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1. INTRODUCTION 
1.1. Sepsis 
Injury induced by a stochastic event, such as trauma or after an operative 
intervention initiates an inflammatory response directed to control the initial insult. 
Patients, who withstand the initial injury, are still at risk to suffer serious deterioration 
of their health by secondary responses mounted after the initiating insult. Such 
secondary responses are commonly sepsis, acute respiratory distress syndrome 
(ARDS) and multiple organ dysfunction syndrome (MODS) (Baue 1975; Meakins 
1990; Baue 1996). Morbidity and mortality associated with these conditions are a 
major health problem (Rangel-Frausto et al. 1995). A national estimate of 751,000 
cases of sepsis is predicted per annum in the U.S, with an average hospital stay of 
19.8 days and costs of approximately $22.100 per case (Angus et al. 2001). 
An intriguing question that arises from clinical observations is the diversity in 
the outcome after severe injury. Thus, it could be hypothesized that the regulation of 
the response to injury is different among human beings, thus resulting in a different 
incidence of sepsis, ARDS and MODS.  
 
1.2. Mediators of sepsis  
Although the patho-physiological mechanism that underlines these syndromes 
is not exactly clear, it seems to proceed from an uncontrolled inflammatory response 
(Livingston et al. 1995). The inflammatory response is composed by the orchestrated 
expression of several factors directed to repair the initial insult. In addition, the 
inflammatory process auto-regulates itself through actions that aim at clearing 
components of the inflammatory cascade. 
Lipopolysaccaride (LPS), or endotoxin, is a component of the outer cell-wall 
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of gram-negative bacteria (Mayeux 1997). In patients with bacteremia, LPS can be 
detected in about 30% of patients (Cohen 2000). LPS is considered to play a key-role 
in human gram-negative septic shock (Kelly et al. 1997). Injection of bacterial LPS to 
healthy volunteers results in a hyper-dynamic metabolic state accompanied by an 
acute inflammatory response, which mimics several aspects of gram-negative sepsis 
(Bone 1992; Mayeux 1997). 
LPS in circulation is recognized by a protein, named LPS-binding protein 
(LBP). The LPS-LBP-complex interacts with a surface receptor on monocytes and 
macrophages, coined CD-14 (Wright et al. 1990). CD-14 is a glycosyl-phospho-
inositol (GPI) anchored glycoprotein, which does not possess any trans-membrane or 
cytosolic domains. Thus, the signal transduction triggered by LPS requires accessory 
membrane associated proteins. One of these accessory proteins is Toll-like receptor 4 
(TLR-4). Via a complex signal transduction pathway activated by TLR-4, the 
transcription factor NF-κB is activated, and is translocated into the nucleus to initiate 
transcription of pro-inflammatory genes that encode for mediators of the 
inflammatory response, such as Tumor Necrosis Factor α (TNF- α) (Beutler et al. 
2001). 
TNF-α belongs to the family of cytokines. They can be divided into two 
major groups: pro-inflammatory cytokines (e.g. TNF-α, IL-1β) that initiate the 
inflammatory response, and anti-inflammatory cytokines (e.g. IL-10), which regulate 
the inflammatory process. The presence of cytokines in circulation is considered a 
good marker of the inflammatory response (Ertel et al. 1993; Volk et al. 1999; 
Hoflich et al. 2002). TNF- α is a pro-inflammatory cytokine that is produced by 
macrophages, monocytes, neutrophile granulocytes, natural killer-cells and 
keratinocytes. The production of TNF- α can also be induced by a vast number of 
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stimuli, such as bacteria, fungi, tumor cells, cytokines like IL-1, IL-2, interferon γ 
(IFN- γ) etc. It is considered a major mediator in the physiological response to shock 
and sepsis with a broad range of effects on cells of the immune system. In addition, 
TNF- α stimulates the proliferation of T- and B-cells, the expression of major 
histocompatibility complex antigens (MHC-I and MHC-II) and modulates the 
expression of adhesion-molecules on endothelial cells. TNF- α also interacts with 
anticoagulation properties of the endothelium and promotes prostaglandin E2 
formation. TNF-α is chemotactic for neutrophils and induces the production of IL-2 
receptors and IFN-γ from T-cells (Aggarwal et al. 1996). TNF- α plasma levels peak 
1.5 to 2h after LPS-injection before going back to baseline (Villa et al. 1995; De 
Maio et al. 1998; Remick et al. 2000). TNF-α has been implicated as major negative 
factor in the clinical outcome from sepsis in humans (Damas et al. 1989; Baud et al. 
1990; Pinsky et al. 1993). However, studies on the effects of anti-TNF-α antibodies in 
humans remain controversial. Most studies could not demonstrate improved survival 
in septic patients (Abraham et al. 1995; Cohen et al. 1996; Reinhart et al. 1996; 
Abraham et al. 1998; Abraham et al. 2001). Interestingly, LPS-induced TNF-α levels 
in the supernatant of monocyte-cultures from healthy humans show inter-individual, 
probably HLA –associated differences (Molvig et al. 1988). Differences in LPS-
induced TNF-α levels between A/J and B6 mice have also been observed and were 
referred to genetic variability within the same species (De Maio et al. 1998). 
Polymorphisms in the TNF-α gene of these two strains have been reported (Iraqi et 
al. 1997, 1999). In humans, at least two polymorphism have been evaluated for their 
association with increased susceptibility to severe sepsis (Stuber et al. 1995; Stuber et 
al. 1996; Fang et al. 1999; Mira et al. 1999; Schroeder et al. 1999; Schroder et al. 
2000; Riese et al. 2003). These findings suggest that genetic diversity may have 
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stronger impact on inter-individual differences than originally anticipated. 
Interestingly, a gender component was described in one of these studies (Schroder et 
al. 2000). 
IL-10 is also produced by macrophages, T lymphocytes and epithelial cells 
and is one of the most important anti-inflammatory cytokines (Moore et al. 1993; 
Oberholzer et al. 2002). IL-10 has a direct role in the down-regulation of several pro-
inflammatory cytokines, particularly TNF-α (Marchant et al. 1994; van der Poll et al. 
1997). Down-regulation of TNF-α by IL-10 occurs at multiple levels including 
transcriptional and posttranscriptional mechanisms (Gerard et al. 1993; Marchant et 
al. 1994; van der Poll et al. 1997). The importance of IL-10 has been illustrated in 
mice lacking the IL-10 gene, which develop symptoms similar to Crohn’s disease 
(Kuhn et al. 1993). Moreover, IL-10 knock out mice injected with bacterial 
lipopolysaccharide (LPS) displayed elevated levels of TNF-α as compared to wild 
type animals (Kuhn et al. 1993). Administration of exogenous IL-10 to female 
BALB/c mice resulted in protection from injection of LPS (Howard et al. 1993). 
Similarly, male BALB/c mice treated with IL-10 were protected from Staphylococcal 
enterotoxin-B (Bean et al. 1993). No protection was observed in female BALB/c 
mice after cecal ligation and puncture (CLP), an experimental model of sepsis 
(Remick et al. 1998). Over-expression of IL-10 improved survival of male B6 mice 
after challenge with E. coli (Takakuwa et al. 2000). Early treatment with anti-IL-10 
antibodies also increased survival of male A/J mice after CLP (Lyons et al. 1999). 
Interestingly, the response to an inflammatory stimulus varies between strains of 
inbred mice. We have previously reported that B6 mice showed higher IL-10 plasma 
levels in comparison with A/J mice after CLP (Stewart et al. 2002). Consequently, a 
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contribution of the genetic background has to be assumed to the inflammatory 
response in general. 
 
1.3. Genetic components in sepsis 
A genetic component in the response to injury has recently been 
demonstrated. Different frequencies of mortality after injection of LPS were observed 
in various mouse strains (De Maio et al. 1998). Similar observations were made after 
CLP (Stewart et al. 2002), and mechanical, thermal and radiation injury (Radojicic et 
al. 1990). Different components of the inflammatory process, such as circulating 
cytokine levels, acute phase gene expression, and infiltration of polymorph-nuclear 
leukocytes in liver and lung have been observed to be different between various 
mouse strains after injection of LPS (De Maio et al. 1998; O'Malley et al. 1998) or 
after CLP (Stewart et al. 2002). Loci contributing to the LPS response have been 
identified in mouse (Matesic et al. 2000). Similarly, mutations in TLR-4 of C3H/HeJ 
and C57BL/10SCr mice have been identified as the responsible factor for their 
resistance to LPS (Qureshi et al. 1996; Poltorak et al. 1998). Studies in humans also 
indicate a genetic component in the response to several inflammatory conditions. The 
polymorphism in the promoter of the human TNF-α gene, 308(G/A), has been 
associated with increased risk of sepsis related mortality (Stuber et al. 1995; Mira et 
al. 1999). The TNFβ, LTα-Nco1 polymorphism of the TNFB locus (TNFB1/2) has 
been correlated with increased mortality of septic patients (Stuber et al. 1996; Fang et 
al. 1999; Schroeder et al. 1999; Schroder et al. 2000), with an increased risk to 
develop severe posttraumatic sepsis (Majetschak et al. 1999) or with higher risk for 
complications after major surgery (Riese et al. 2003). Similarly, Tnf polymorphisms 
are associated with negative outcome from other infectious diseases, such as cerebral 
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malaria (McGuire et al. 1994), leishmaniasis (Cabrera et al. 1995), and autoimmune 
diseases, such as systemic lupus erythematosus (Jacob et al. 1991). Consequently, 
genetic diversity has to be taken into account to explain the variable response 
observed in patients and in order to identify risk-factors that predict increased 
susceptibility to develop severe sepsis after a major injury. 
  
1.4. Gender as a risk factor for the outcome from sepsis 
Another confounding factor in the response to injury is gender. Male gender 
has been associated with a higher risk of infections after injury (Offner et al. 1999). 
After surgery, male patients require therapy in the surgical intensive care unit more 
frequently than females and have higher incidence of severe sepsis and septic shock 
as compared to females (Wichmann et al. 2000). Females from different species have 
been demonstrated to be more resistant to bacterial, viral, and parasitic infections 
(Klein 2000). In general, female rodents have an enhanced immunological response 
with respect to males, resulting in better survival after injury (Zellweger et al. 1997; 
Angele et al. 2000). In particular, cytokine-secretion (IL-1, IL-2, IL-3, and IL-6) from 
isolated peritoneal and splenic macrophages from C3H/HeN mice after hemorrhagic 
shock were higher in females than in males (Wichmann et al. 1996). Similar studies 
provide evidence that female C3H/HeN mice are immunologically more competent 
than male mice after CLP (Zellweger et al. 1997). Gender differences have also been 
demonstrated in the response after burn injury in BALB/c mice (Gregory et al. 2000). 
This lower susceptibility of females to different insults has been explained by the 
presence of sex steroids. 
Castrated C3H/HeN male mice supplemented with 5α-dihydrotestosterone 
(DHT) show a decrease in the levels of pro-inflammatory cytokines after hemorrhagic 
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shock with respect to non-castrated mice. These findings were prevented when 
castrated male mice were supplemented with EST (Angele et al. 1999). A decrease in 
testosterone levels by either surgical castration or pharmacological blockage has been 
shown to be beneficial in C3H/HeN male mice after hemorrhagic shock (Remmers et 
al. 1997; Wichmann et al. 1997; Remmers et al. 1998). 
However, controversial findings have been made in studies that found no 
gender difference (Riche et al. 1996; Eachempati et al. 1999; Wichmann et al. 2000), 
or an even higher mortality in septic female patients (McLauchlan et al. 1995; 
Napolitano et al. 2001; O'Keefe et al. 2001). Some authors even described higher 
incidence of infection in female patients (Dinkel et al. 1994; Kollef et al. 1997). In 
summary, it seems as if there is no general consensus whether gender is a positive or 
negative factor in the outcome from injury and how such controversial findings may 
be interpreted. 
Interestingly, differences in TNFB gene distribution of septic patients have 
been correlated with a better outcome in females as compared to males (Schroder et 
al. 2000). It is possible that genetic variability has major impact on gender differences 
in the inflammatory response or its modulation by sex-steroids and thus may explain 
controversial observations on gender as a potential risk-factor that determines the 
outcome from severe sepsis.  
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2. AIMS OF THE STUDY 
 
We hypothesized that gender differences are also dependant on genetic traits. Since it 
is well-anticipated that sex-steroids are most likely responsible for gender differences, 
the effect of sex-steroids on the inflammatory process was investigated. To test this 
hypothesis, we designed an experimental model to answer the following question: 
 
• Is gender a contributing factor to the LPS-induced inflammatory response? 
• Can sex-steroids or hormone depletion by surgical castration modulate this 
response? 
• Is this modulation dependent of the genetic background of the individual? 
• Do sex-chromosomes carry information that is responsible for a variable 
response? 
• Do changes in the response that were induced with sex-steroids or hormone 
depletion affect the outcome from endotoxic shock? 
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3. MATERIAL AND METHODS 
 
3.1. Animals 
Male and female A/J, AKR/J, BALB/cJ, C57BL/6J (herein designated as B6), and 
DBA/2J mice at the age of 6 weeks were obtained from Jackson Laboratory (Bar 
Harbor, Maine). Additional male C3H/HeN mice were purchased from Charles River 
Laboratory (Portage, Michigan).  
B6AF1 mice (F1-generation; herein designated as B X A), the offspring from 
a B6 female and an A/J male were purchased from Jackson Laboratory (Bar Harbor, 
Maine). F1s bred from an A/J female and a B6 male are not commercially available. 
Hence, AB6F1, (herein designated as A X B) were bred in our laboratory animal 
facility. 
All mice were maintained under identical environmental conditions in a 
pathogen-free animal facility. All procedures were carried out in accordance with the 
guidelines for the Care and Use of Laboratory Animals by the National Institutes of 
Health (NIH). The experimental protocol was approved by the Institutional Animal 
Care and Use Committee of Johns-Hopkins-University School of Medicine. 
 
3.2. Castration 
Male mice (6 weeks old) were anesthetized with an intraperitoneal injection of 
Avertin (400 to 500 mg/kg body weight). Avertin, a common rodent anesthetic, was 
composed of 0.9 mM 2,2,2 tribromoethanol (Aldrich Chemical Company, 
Milwaukee, Wisconsin) in an aqueous solution of 0.5 % (V/V) tert-amyl alcohol 
(Aldrich Chemical Company, Milwaukee, Wisconsin). After anesthesia, the abdomen 
was opened by low midline laparotomy, testicles were exposed from the scrotum, and 
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were removed after ligation with a single suture (Silk 4-0; Ethicon Inc., Somerville, 
New Jersey). The abdominal incision was closed in two layers with absorbable suture 
(Polysorb 4-0; USSC, Norfalk, Connecticut). No mortalities were observed in 
castrated mice without LPS challenge. 
 
3.3. Ovariectomy 
Female mice (6 weeks old) were anesthetized with an intraperitoneal injection 
of Avertin (400 to 500 mg/kg body weight). Each ovary was accessed via a small 
paravertebral incision between the lower rim of the rib cage and the upper pelvic 
ridge. The oviduct and adjacent blood vessels were ligated using a single suture (Silk 
4-0; Ethicon Inc., Somerville, New Jersey). The ovaries were then removed and the 
incisions were closed in two layers with absorbable suture (Polysorb 4-0; USSC, 
Norfalk, Connecticut). No mortalities were observed in ovariectomized mice without 
LPS challenge. 
 
3.4. Hormone supplementation  
Protocol and dosage used in this experiment were followed as previously 
described (Angele et al. 1999): Following gonadectomy, hormone release pellets 
(Innovative Research of America, Sarasota, Florida) were implanted through a small 
dorsal incision into a subcutaneous pocket. These pellets release constant daily doses 
of hormone for up to 21 days: 0.357 mg/d of 5-α-Dihydrotestosterone (DHT), or 23.8 
µg/d of 17-β-Estradiol (EST). Vehicle pellets that do not contain any active hormone 
served as placebo (VEH). After surgery, mice were allowed to recover for 2 weeks 
prior to further manipulations. Injection of saline in gonadoctomized and hormone 
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supplemented mice did not result in any significant TNF-α or IL-10 plasma levels 
(Figure 1a+b). 
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 Figure 1 a+b: TNF-α (Fig. 1a, top) and IL-10 (Figure 1b, bottom) plasma levels in male A/J mice 14 days 
after recovery from surgical castration. Six week old mice were castrated and received hormonal treatment 
with 5-α-Dihydrotestosterone (DHT) or 17-ß-Estrogen (EST) by hormone release pellets implanted during 
surgery. One group received pellets which do not contain any hormone (VEH). Additional, non-manipulated 
mice were used as control (CONT). Afterwards, all mice were maintained under identical conditions for two 
weeks. After fasting for 16h, mice received an intra-peritoneal injection of normal saline (-LPS). Some CONT 
mice received an injection of LPS (15mg/kg; CONT + LPS). After 1.5h of the injection plasma was obtained. 
Plasma cytokine levels were measured using an ELISA. The cytokine levels correspond to the average 
concentration obtained from each group ± standard error of the mean. As opposed to the high levels of cytokine 
induced in non-manipulated male A/J mice injected with LPS, castration and implantation of pellets (DHT, 
EST, VEH) did not result in any significant cytokine response after injection of normal saline. 
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3.5. Endotoxemia 
At the age of 8 weeks, mice were subjected to endotoxic shock. By now, 
gonadectomized animals had recovered for 2 weeks. Mice were fasted for 16 h with 
access to water ad libitum. Then, they were intraperitoneally injected with E. coli 
026:B6 LPS (15 mg/kg) (Diffco Laboratories, Detroit, Michigan) under aseptical 
conditions. After 1.5 hours of the injection, animals were anesthetized with Avertin 
and blood was drawn from the right ventricle after cardiac puncture, and collected 
into potassium-EDTA-coated Microtainer™ tubes (Becton Dickinson; Franlin Lakes, 
New Jersey). The same batch of LPS was used throughout all described experiments. 
Plasma levels of TNF-α and IL-10 were measured using a commercial ELISA-kit 
(BioSouce International Inc.; Camarillo, California). In the morality experiments, 
mice were treated as described, however survival was monitored up to 150h without 
any further intervention. 
 
3.6. Vaginal smears 
Smears were obtained by lavage of the vagina with approximately 18 µL of 
normal saline, injected through a 24G Teflon catheter on top of a 20 µL pipette. The 
sample was put into an Eppendorf™ tube. For better contrast and staining of nuclei, a 
drop of methylene-blue was added. The sample was mixed well and than spread out 
on a slide for microscopic evaluation.  
We used modified criteria to determine the stages of estrus cycle based on 
Rugh (Rugh 1990): When the majority of cells in the smear were leukocytes, the 
sample was classified as diestrus. When clearly defined epithelial cells, some with 
distinct nuclei or large, squamous epithelial cells without nuclei were observed, the 
smear was considered estrus. Intermediate stages were not further discriminated (For 
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further detail on the murine estrus cycle see APPENDIX 1: On the Estrus Cycle of 
the Mouse.)  
 
3.7. Statistical analysis 
The Kruskal-Wallis One Way Analysis of Variance (ANOVA) on ranks with 
the 1 to k correction by Dunn was performed to determine the effect of different 
hormonal treatment with respect to untreated controls (CONT). Differences between 
two independent groups were evaluated by non-parametric comparison with Mann-
Whitney-Rank Sum Test as indicated. Survival as categorical variable was analyzed 
using the Fisher Exact Test.  
Data are expressed as mean ± standard error of the mean (SEM) unless stated 
otherwise. Statistical significance was accepted at p<0.05. 
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4. RESULTS 
4.1. Gender differences in TNF-α plasma levels and the role of sex steroids 
We compared the response to LPS between female and male B6 mice. Mice 
were injected with LPS (15mg/kg), which results in significant mortality within 48h, 
as previously reported (De Maio et al. 1998). Blood samples were taken 1.5 h after 
LPS injection for analysis of TNF-α plasma levels. This time point corresponds to the 
maximum detectable plasma level of this cytokine after this dose of LPS (De Maio et 
al. 1998). Female B6 mice showed TNF-α plasma levels that were two-fold higher 
than B6 male mice (Figure 2). These results reflected several independent 
determinations performed during 10 months to account for different stages of the 
estrus cycle in female mice and potential seasonal variability. 
To test for possible influence of the estrus cycle, vaginal smears from an 
additional set of female mice was taken just before the injection of LPS. When LPS-
induced TNF-α plasma levels were stratified by “estrus” and “diestrus” stage of the 
murine estrus cycle, no significant difference between females in estrus or diestrus 
could be detected (Figure 3). Only a trend towards lower TNF-α plasma levels of 
estrus (i.e. high estrogen) mice was observed. However, female B6 mice in diestrus 
(i.e. low estrogen) had significantly higher TNF-α levels than male B6 mice, 
confirming the observed gender-difference. Comparison of male B6 mice with female 
B6 mice in estrus did not show this difference. 
Thus, the difference in LPS induced-TNF-α levels between females and males 
could be due to the presence of sex-steroids. To test this possibility, female and male 
B6 mice were gonadectomized at 6 weeks of age and supplemented with 17-β-
estradiol (EST), 5-α-dihydrotestosterone (DHT) or the vehicle as placebo (VEH). 
 15
 
Figure 2: Gender differences in TNF- α levels 1.5h after injection with 
LPS. A/J male, A/J female, B6 male and B6 female mice at the age of 8 weeks 
were injected with LPS (15 mg/kg). Plasma samples were taken 1.5h after the 
injection. TNF- α was measured using an ELISA. The cytokine levels 
correspond to the average concentration obtained from all animals in the group 
± standard error of the mean. Statistical significance was accepted at *p<0.05 
obtained by pair wise comparison as indicated by lines, using Mann-Whitney-
Rank Sum Test. 
 
Two weeks after the intervention, mice were injected with LPS and plasma TNF-α 
levels were evaluated in plasma samples obtained 1.5 h after the injection. Castration 
of male mice without hormone replacement (VEH) resulted in a two-fold increase of 
LPS- induced TNF-α levels suggesting a suppressive effect caused by testosterone. 
Addition of EST to the castrated male mice resulted in a further increase of TNF-α  
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Figure 3: Gender differences and hormonal influence on LPS-induced 
TNF- α levels in B6 mice after injection with LPS. At the age of 8 weeks, 
B6 female and B6 female in diestrus or in estrus were injected with LPS 
(15mg/kg). Plasma samples were taken 1.5h after the injection. LPS-induced 
plasma levels of TNF-α were measured using an ELISA and were compared 
to those of B6 male mice after 1.5h of LPS injection. Additionally, female B6 
mice at the age of 6 weeks were ovariectomized and treated with estradiol 
pellets (feEST) or vehicle (feVEH). After 14 days of recovery, mice were 
injected with LPS as described and blood sample were taken 1.5h after the 
injection. Plasma was obtained and TNF-α levels were measured. Cytokine 
levels in each female group were compared to LPS-induced TNF-α plasma 
levels of male B6 mice by pair wise comparison. The cytokine levels 
correspond to the average concentration obtained from all animals in the 
group ± standard error of the mean. Statistical significance was accepted at 
*p<0.05 obtained by pair wise comparison with respect to B6 males using 
Mann-Whitney-Rank Sum Test. 
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levels (3-fold) indicating an enhancing effect of this hormone. Administration of 
DHT resulted in LPS-induced TNF-α plasma levels similar to non-operated mice 
(CONT). LPS-induced TNF-α levels in EST supplemented B6 male mice were also 
higher (1.5 fold) than non-operated female mice (p < 0.022). 
Female B6 mice showed no effect of ovariectomy or hormone replacement 
in the TNF-α plasma levels induced by injection of LPS (Table 1). Examination of 
vaginal smears obtained from ovariectomized female mice supplemented with EST 
showed the typical pattern of the estrus stage. In contrast, the pattern of female mice 
supplemented with DHT or placebo corresponded to a diestrus-like stage. 
These results suggest a modifier role for sex-steroids in LPS-induced TNF-α 
response in male B6 mice. However, hormonal manipulation did not alter the 
response of female mice, arguing against that modifier role of sex-steroids. It is 
possible that other sex-related factors, such as genetic differences are involved in the 
response to LPS of female and male mice. 
To determine if gender differences underlie variability based on genetic 
differences within strains of inbred mice and thus are dependant on the genetic 
background, we repeated the experiment in A/J mice. This strain has previously been 
demonstrated to show a distinctive response to LPS in comparison with B6 mice (De 
Maio et al. 1998; O'Malley et al. 1998; Matesic et al. 1999; Matesic et al. 2000; 
Stewart et al. 2002). Male A/J mice were found to have higher LPS-induced TNF-
α plasma levels than B6 males (De Maio et al. 1998). 
When LPS-induced TNF-α plasma levels of male A/J mice were compared 
with females, no gender difference was detected (Figure 2). Since females were not 
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 CONT VEH EST DHT 
 4400 ±503 2926 ±374 1743 ±261 3573 ±452 
AJ male  n= 39 n= 21 n= 19 n= 22 
      ↓ * x2.5   
 4719 ±488 3817 ±526 3171 ±500 3832 ±418 
AJ female  n= 60 n= 18 n= 21 n= 17 
          
 2086 ±279 4158 ±763 6298 ±844 3130 ±377 
B6 male  n= 43 n= 15 n= 11 n= 9 
    ↑ * x2 ↑ * x3   
 4158 ±388 5655 ±975 4649 ±463 3051 ±435 
B6 female  n= 50 n= 10 n= 10 n= 9 
          
 
Table 1: Comparison of LPS-induced TNF-α plasma levels between male and female 
B6 mice at the age of 8 weeks. Gonadectomized mice were operated on at the age of 6 
weeks and treated with EST, DHT or VEH released from hormone pellets implanted during 
surgery and followed by a two-week recovery period. Non-operated mice were used as 
controls (CONT). All mice were maintained under identical conditions. Mice were injected 
with LPS (15mg/ml) and TNF-α plasma levels were measured. Data corresponds to the 
average TNF-α concentration obtained from each group ±standard error of the mean. 
Arrows indicate an increase (↑) or decrease (↓) of TNF-α plasma levels. Statistical 
significance was accepted at *p<0.05 obtained by ANOVA on Ranks and Dunn's Method as 
Post Hoc test with respect to CONT. 
 
stratified by the stage of the estrus cycle, possible gender differences related to 
changes in hormonal levels throughout the estrus cycle may have been masked. 
Therefore, vaginal smears were obtained from an additional set of female A/J mice. 
The findings suggest a similar, albeit statistically not significant trend as observed in 
B6 females: stages of low estrogen levels (i.e. diestrus) are associated with high 
levels of LPS-induced TNF-α and stages of high estrogen (i.e. estrus) are associated 
with low TNF-α levels (Figure 4).  
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 Figure 4: Gender differences and hormonal influence on LPS-induced TNF- α 
levels in A/J mice after injection with LPS. At the age of 8 weeks, A/J female and A/J 
female in diestrus or in estrus were injected with LPS (15mg/kg). Plasma samples were 
taken 1.5h after the injection. LPS-induced plasma levels of TNF-α were measured 
using an ELISA and were compared to those of A/J male mice after 1.5h of LPS 
injection. Additionally, female A/J mice at the age of 6 weeks were ovariectomized and 
treated with estradiol pellets (feEST) or vehicle (feVEH). All mice were maintained 
under identical conditions. After 14 days of recovery, mice were injected with LPS as 
described and blood sample were taken 1.5h after the injection. Plasma was obtained 
and TNF-α plasma levels were measured. The cytokine levels correspond to the average 
concentration obtained from all animals in the group ± standard error of the mean. 
Statistical significance was accepted at *p<0.05 obtained by pair wise comparison with 
respect to A/J males using Mann-Whitney-Rank Sum Test 
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To evaluate the potential of sex-steroids to modulate TNF-α levels in this 
strain, A/J mice were gonadectomized and treated with hormone pellets releasing 
DHT or EST. An additional group was supplied with placebo pellets (VEH). In A/J 
male mice, there was no significant effect of castration without hormonal replacement 
(VEH) in LPS-induced TNF-α plasma levels. After treatment with EST, a decrease in 
LPS-induced TNF-α levels was observed. Ovariectomy and implantation of pellets, 
releasing either DHT, EST or VEH respectively, did not affect TNF-α plasma levels 
after injection of LPS in any female A/J group (Table 1). It appears that sex steroids 
can only modify the LPS-induced inflammatory response in male mice.  
 
4.2. Effect of 17-β-EST on TNF-α plasma levels varies with the genetic 
background 
We assessed whether the effect of EST on LPS-induced TNF-α plasma levels 
was particular to B6 mice or if it could be observed in other mouse strains. Male mice 
of the inbred strains AKR/J, DBA/2J, and BALB/cJ were included into the study. 
Statistically different levels of plasma TNF-α after LPS injection in non-manipulated 
mice were observed in these strains resulting in the following hierarchy: DBA/2J > 
AKR/J = BALB/cJ = A/J >B6 (Table 2, Mann-Whitney Rank-Sum-Test, p<0.05). 
There was no significant effect of castration without hormonal replacement (VEH) in 
LPS-induced TNF-α plasma levels in any of these mouse strains other than B6. All of 
them showed a decrease in LPS-induced TNF-α levels after treatment with EST, 
which is contrary to the values observed in B6 mice (Table2). 
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Table 2: Modulation of LPS-induced TNF-α plasma levels in male mice from different 
inbred strains after estradiol treatment. A/J, AKR/J, DBA/2J, BALB/cJ and B6 were 
castrated and supplemented with EST or VEH pellets. Non-operated mice were used as 
controls (CONT). Mice were injected with LPS (15mg/ml) and TNF-α plasma levels were 
measured. Data corresponds to the average TNF-α concentration obtained from each group 
±standard error of the mean. Arrows indicate increase (↑) or decrease (↓) of TNF-α plasma 
levels. Statistical significance was accepted at *p<0.05 obtained by ANOVA on Ranks & 
Dunn's Method as Post Hoc test with respect to CONT. 
 
4.3. IL-10 plasma levels in male and female B6 and A/J mice and the role of sex 
steroids 
Male and female mice of B6 and A/J strain were injected with LPS (15 
mg/kg) and blood samples were collected after 1.5 h for IL-10 detection. For this 
time-point, plasma IL-10 levels were observed to be maximal and with higher levels 
in B6 mice. However, there were no differences in LPS-induced IL-10 plasma levels 
between females and males of each strain (Figure 5). The data represents several 
independent experiments performed during a time period of 10 months to include 
possible seasonal variability. Moreover, female mice were not differentiated by the 
stage in the estrus cycle. Thus, this data represents the average of possible differences 
due to hormonal changes between males and females. 
 A/J AKR DBA BALB/cJ B6 
 4400 ±503 6070 ±1031 12196 ±1624 3917 ±442 2086 ±279
CONT  n= 39 n= 8 n= 8 n= 10 n= 43 
            
 2926 ±374 6503 ± 1148 9916 ±781 5476±1498 4158 ±763
VEH  n= 21 n= 8 n= 8 n= 10 n= 15 
          ↑ * x2 
 1743 ±261 4110 ±306 7480 ±1183 2365 ±254 6298 ±844
EST  n= 19 n= 8 n= 8 n= 8 n= 11 
  ↓ * x2.5 ↓ * x1.5 ↓ * x1.6  ↓ * x1.7 ↑ * x3 
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An additional set of A/J and B6 female mice was obtained and stages of the 
estrus cycle were determined just before the injection of LPS. While no effect of 
estrus or diestus was detected in B6 females (Figure 6), A/J females in estrus (high 
estrogen) showed a trend towards increased IL-10 plasma levels (Figure 7). Thus a 
possible influence of sex-steroid on LPS-induced IL-10 plasma levels could not be 
excluded at least for the A/J strain. This finding implicates that hormonal effects 
might create differences between males and females although no relevant gender 
difference in LPS-induced IL-10 plasma levels was observed. 
Thus, mice were gonadectomized at the age of 6 weeks and supplemented 
with pellets that release a daily dose of DHT or EST. These mice were maintained 
under hormonal replacement conditions for two weeks. As a control, gonadectomized 
mice were supplemented with pellets that release no hormones (VEH). After two 
weeks of hormone replacement, mice were injected with LPS and IL-10 plasma levels 
were detected 1.5 h after the injection. The three groups were compared with mice 
that were not operated, but maintained under the same environmental conditions as 
the manipulated rodents (CONT). Gonadectomy and treatment with placebo pellets 
(VEH) did not affect the LPS-induced IL-10 plasma levels of neither male nor female 
B6 mice (Table 3). However, EST treatment increased LPS-induced IL-10 levels in 
both sexes. On the contrary, DHT did not affect LPS-induced IL-10 levels in any sex. 
In A/J mice a comparable response was observed (Table 3). While DHT had no 
effect on IL-10 plasma levels, EST markedly increased IL-10 plasma levels in male 
and female mice respectively. Interestingly, ovariectomy in A/J females without 
hormonal replacement (VEH) resulted in an increase of LPS-induced IL-10 levels 
(2.3 fold) whereas castration did not have such an effect on male A/J mice (Table 3).
 23
 
Figure 5: Gender differences in IL-10 plasma levels after injection with LPS. A/J 
male, A/J female, B6 males, B6 females mice at the age of 8 weeks were injected with 
LPS (15 mg/kg). Blood samples were taken 1.5h after injection. Plasma was obtained and 
IL-10 was measured by an ELISA. The cytokine levels corresponded to the average 
concentration obtained from each group ± standard error of the mean. The data was 
collected during the course of ten months to include possible seasonal variability and 
possible differences in the estrus cycle of female mice. LPS-induced IL-10 plasma levels 
were increased in both, male and female B6 mice as opposed to the A/J strain. Statistical 
significance was accepted at *p<0.05 obtained by pair wise comparison with respect to 
males using Mann-Whitney-Rank Sum Test. 
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Figure 6: Gender differences and hormonal influence on LPS-induced IL-10 levels in 
A/J mice after injection with LPS. At the age of 8 weeks, A/J female and A/J female in 
diestrus or in estrus were injected with LPS (15mg/kg). Plasma samples were taken 1.5h after 
the injection. LPS-induced plasma levels of IL-10 were measured by the use of ELISA and 
were compared to those of A/J male mice after 1.5h of LPS injection. Additionally, female B6 
mice at the age of 6 weeks were ovariectomized and treated with estradiol pellets (feEST) or 
vehicle (feVEH). After 14 days of recovery, mice were injected with LPS as described and 
blood sample were taken 1.5h after the injection. Plasma was obtained and TNF-α plasma 
levels were measured. Cytokine levels in each female group were compared to LPS-induced 
TNF-α plasma level of male A/J mice by pair wise comparison. The cytokine levels 
correspond to the average concentration obtained from all animals in the group ± standard 
error of the mean. Statistical significance was accepted at *p<0.05 obtained by pair wise 
comparison with respect to B6 males using Mann-Whitney-Rank Sum Test. 
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Figure 7: Gender differences and hormonal influence on LPS-induced IL-10 levels in 
A/J mice after injection with LPS. At the age of 8 weeks, A/J female and A/J female in 
diestrus or in estrus were injected with LPS (15mg/kg). Plasma samples were taken 1.5h 
after the injection. LPS-induced plasma levels of IL-10 were measured using an ELISA 
and were compared to those of A/J male mice after 1.5h of LPS injection. Additionally, 
female A/J mice at the age of 6 weeks were ovariectomized and treated with estradiol 
pellets (feEST) or vehicle (feVEH). After 14 days of recovery, mice were injected with 
LPS as described and blood sample were taken 1.5h after the injection. Plasma was 
obtained and IL-10 plasma levels were measured. This data was included into the 
comparison. Cytokine levels in each female group were compared to LPS-induced IL-10 
plasma level of male A/J mice by pair wise comparison. The cytokine levels correspond to 
the average concentration obtained from all animals in the group ± standard error of the 
mean. Statistical significance was accepted at *p<0.05 obtained by pair wise comparison 
with respect to A/J males using Mann-Whitney-Rank Sum Test. 
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 CONT VEH EST DHT 
 1920 ±216 3157 ±582 5293 ±893 2323 ±324 
A/J male n= 32 n= 21 n= 19 n= 22 
   ↑ * x2.8  
 2110 ±139 4846 ±800 7321 ±829 3053 ±446 
A/J female n= 52 n= 18 n= 21 n= 17 
  ↑ * x2.3 ↑ * x3.5  
 3228 ±310 3932 ±519 6060 ±706 4280 ±706 
B6 male n= 32 n= 15 n= 11 n= 9 
   ↑ * x1.9  
 3322 ±252 4558 ±1130 10231 ±886 4113 ±646 
B6 female n= 37 n= 10 n= 10 n= 9 
   ↑ * x3.1  
 
Table 3: LPS-induced IL-10 plasma levels in eight week old male and female A/J and 
B6 mice treated with different sex steroids. Male mice were castrated and females were 
ovariectomized at the age of 6 weeks respectively. Mice were supplemented with 
subcutaneous hormone pellets of 17-β-estradiole (EST), 5-α-dihydroxytestosterone (DHT) 
or placebo (VEH) for 14 days and than injected with LPS (15mg/kg). Cytokine plasma 
levels were measured using an ELISA. The data correspond to the average of each group± 
standard error of the mean. Arrows indicate increase (↑) of plasma levels. Statistical 
significance was accepted at p<0.05 (*) obtained by ANOVA on Ranks & Dunn's Method as 
Post Hoc test with respect to CONT. 
 
4.4. 17-β-Estradiole enhancement of IL-10 plasma levels during endotoxemia is 
determined by the genetic background 
The importance of the genetic background on the response to EST was further 
elucidated by employing other inbred strains. Male AKR/J, DBA/2J, and BALB/cJ 
were castrated and supplemented with EST or VEH pellets and compared with non-
operated mice. LPS-induced IL-10 plasma levels in the non-operated group were very 
different among the various strains. Statistical differences in IL-10 levels of these 
strains resulted in the following hierarchy: BALB/cJ >AKR/J =B6 > A/J =DBA/2J 
(Table 4, Mann-Whitney Rank-Sum-Test, p<0.05). Castration and VEH treatment did 
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not affect LPS-induced IL-10 levels in any studied strain. Administration of EST 
resulted in an increase of LPS-induced IL-10 levels in AKR/J similar to A/J and B6 
mice. DBA/2J and BALB/cJ did not demonstrate any further increase of LPS-induced 
IL-10 levels after administration of EST (Table 4). This data indicates that the 
response to EST is genetically modulated. 
 
 A/J AKR DBA BALB/cJ B6 
 1920 ±216 2918 ±568 1348 ±124 5117 ±484 3228 ±310 
CONT  n= 32 n= 8 n= 7 n= 10 n= 32 
            
 3157 ±582 4158 ±773 1267 ±144 6270 ±952 3932 ±519 
VEH  n= 21 n= 8 n= 8 n= 10 n= 15 
  x1.6         
 5293 ±893 8375 ±1934 1467 ±223 4292 ±274 6060 ±706 
EST  n= 19 n= 8 n= 8 n= 8 n= 11 
  ↑ * x2.8 ↑ * x2.9     ↑ * x1.9 
 
Table 4: LPS-induced IL-10 plasma levels in male mice from different inbred strains after 
castration and estrogen treatment. Male A/J, AKR/J, DBA/2J, BALB/cJ and B6 mice were 
castrated at the age of 6 weeks, treated with subcutaneous hormone pellets of 17-β-estradiol 
(EST) or placebo (VEH) for 14 days and injected with LPS (15mg/kg). Blood samples were 
collected 1.5h after LPS injection. Cytokine plasma levels were obtained using an ELISA. The 
displayed cytokine levels correspond to the average concentration obtained from each group ± 
standard error of the mean. Arrows indicate increase (↑) or decrease (↓) of TNF-α plasma levels. 
Statistical significance was accepted at *p<0.05 obtained by ANOVA on Ranks & Dunn's 
Method as Post Hoc test with respect to CONT. 
 
4.5. Investigation of sex-link of the observed phenotypes in the F1 generation 
Apart from sex-steroids another possible variable that may be responsible for 
gender differences are the sex-chromosomes. To evaluate if sex-chromosomes are 
involved in the observed phenotypes we analyzed LPS-induced inflammatory 
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response in the F1-generation bred from B6 and A/J mice. The offspring of two 
homozygous founder strains generates mice that are heterozygous in every single 
allele except from the sex-chromosomes. Since the Y-chromosome of a male F1 
mouse may be contributed by an A/J or B6 father, both possible alternatives (A X B or 
B X A) were included. Moreover, this approach would give a rough idea on the 
inheritance pattern of the observed phenotypes. 
Non-operated male and female F1 mice have a TNF-α phenotype similar to 
B6 male mice at 1.5h after injection of LPS (Figure 8). This suggests that this 
phenotype is neither sex-linked nor imprinted, and may be a B6 dominant, autosomal 
allele. Evaluation of the IL-10 phenotype in F1 mice clearly indicates that LPS-
induced IL-10 plasma levels in B X A male and female mice follow the same pattern 
than B6 mice (Figure 9). However, IL-10 plasma levels in A X B males and females 
do not match the pattern in either A/J or B6. The data suggests comparable IL-10 
levels between A/J males and A X B males (Figure 9). This might suggest 
involvement of the A/J X-chromosome. However, the levels of A X B females seem 
to be comparable to B6 mice. Moreover, IL-10 plasma levels of A X B male and 
female mice do not differ statistically (p=0.35 in a pair wise comparison by Mann-
Whitney-Rank Sum Test). If IL-10 levels of A X B males and females were 
comparable to the B6 founder strain, no sex-link or imprinting could be postulated for 
this phenotype. Male F1 mice were also castrated and supplemented with sex-
steroids. The levels of LPS-induced TNF-α were neither modified by castration and 
administration of vehicle (VEH) nor castration and hormone treatment (i.e. EST or 
DHT; Table 5). Thus, the effect of EST on LPS-induced TNF-α plasma levels in the 
parental generation and the effect of castration on male B6 mice disappear with the 
loss of homozygosity. Another explanation for the loss of these changes might be that 
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opposing alleles neutralize each other when combined in the same individual. No 
effects were observed in female F1 mice (Table 5). 
Figure 8: Comparison of LPS-induced TNF-α plasma levels in A/J, B6 and 
their F1-generation. Male A/J, AxB, BxA and B6 mice and female A/J, AxB, 
BxA and B6 mice at the age of 8 weeks were injected with LPS (15 mg/kg). 
Blood samples were taken 1.5h after injection. Plasma was obtained and TNF-α 
was measured using an ELISA. The displayed cytokine levels correspond to the 
average concentration obtained from each group ± standard error of the mean. 
Statistical significance was accepted at *p<0.05 obtained by pair wise comparison 
with respect to B6 males using Mann-Whitney-Rank Sum Test. 
AJmale AJfemale B6male B6female AxBmale BxAmale AxBfemale BxAfemale
TN
F-
α
 p
la
sm
a 
le
ve
ls
 (p
g/
m
l)
0
5000
10000
15000
20000
25000
(n= 39) (n= 43)
* 
(n= 60) (n= 10) (n= 10)(n= 50) (n= 8) (n= 10)
 30
 CONT VEH EST DHT 
 2211 ±165 2777 ± 339 2289 ±314 3195 ±531 
AxB males n= 10 n= 10 n= 8 n= 10 
         
 3302 ±946 5279 ±1605 4030 ±1140 2826 ±687 
AxB females n= 8 n= 8 n= 7 n= 7 
         
 1772 ±173 2748 ±292 3073 ±499 2443 ±188 
BxA males n= 10 n= 12 n= 9 n= 12 
         
 1992 ±182 2490 ±191 2710 ±165 2625 ±239 
BxA females n= 10 n= 12 n= 12 n= 12 
          
 
Table 5: LPS-induced TNF-α plasma levels in the F1-Generation of A/J and B6 mice 
after castration and hormonal treatment. Male and female F1 mice were bred from A/J 
and B6 parental generation. Male and female AxB and BxA were gonadectomized at the 
age of 6 weeks respectively, and treated with subcutaneous hormone pellets of 17-β-
estradiol (EST) or placebo (VEH) for 14 days. On the day of the experiment they were 
injected with LPS (15mg/kg). Blood samples were collected 1.5h after LPS injection. 
Cytokine plasma levels were obtained using an ELISA. The displayed cytokine levels 
correspond to the average concentration obtained from each group ± standard error of the 
mean. Arrows indicate increase (↑) or decrease (↓) of TNF-α plasma levels. Statistical 
significance was accepted at *p<0.05 obtained by ANOVA on Ranks & Dunn's Method as 
Post Hoc test with respect to CONT. 
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The effects of gonadectomy and implantation of hormone or VEH pellets had a 
similar effect on IL-10 plasma levels in F1 mice as on the parental generation: 
Gonadectomy with VEH-treatment or DHT-treatment respectively had no effect on 
LPS-induced IL-10 levels. EST-treatment clearly increased IL-10 levels in male A X 
B, male B X A and females B X A mice. In female A X B mice however, the increase 
failed statistical significance (Table 6). 
 
Figure 9: Comparison of LPS-induced IL-10 plasma levels in A/J, B6 and their F1-
generation. Male A/J, AxB, BxA and B6 mice and female A/J, AxB, BxA and B6 mice at the 
age of 8 weeks were injected with LPS (15 mg/kg). Blood samples were taken 1.5h after 
injection. Plasma was obtained and IL-10 plasma levels were measured using an ELISA. The 
displayed cytokine levels correspond to the average concentration obtained from each group ± 
standard error of the mean. Statistical significance was accepted at *p<0.05 obtained by pair 
wise comparison with respect to A/J or AxB males females respectively by using Mann-
Whitney-Rank Sum Test. 
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 CONT VEH EST DHT 
 2341 ±214 3532 ±554 6986 ±904 3885 ±982 
AxB males n= 10 n= 10 n= 8 n= 10 
     ↑ * x3   
 3169 ±605 3186 ±398 4795 ±736 3248 ±587 
AxB females n= 7 n= 8 n= 7 n= 6 
     x1.5   
 3516 ±270 5012 ±510 8736 ±1916 3526 ±329 
BxA males n= 9 n= 12 n= 9 n= 12 
     ↑ * x2.5   
 3128 ±216 3796 ±305 9254 ±665 3506 ±178 
BxA females n= 10 n= 12 n= 12 n= 12 
     ↑ * x3   
 
Table 6: LPS-induced IL-10 plasma levels in the F1-Generation of A/J and B6 mice after 
castration and hormonal treatment. Male and female F1 mice were bred from A/J and B6 
parental generation. Male and female AxB and BxA were gonadectomized at the age of 6 
weeks respectively, treated with subcutaneous hormone pellets of 17-ß-estradiol (EST) or 
placebo (VEH) for 14 days and were injected with LPS (15mg/kg). Non-operated mice were 
used as control (CONT). All mice were maintained under identical environmental conditions. 
Blood samples were collected 1.5h after LPS injection. Cytokine plasma levels were obtained 
using an ELISA. The displayed cytokine levels correspond to the average concentration 
obtained from each group ± standard error of the mean. Arrows indicate increase (↑) or 
decrease (↓) of IL-10 plasma levels. Statistical significance was accepted at *p<0.05 obtained 
by ANOVA on Ranks & Dunn's Method as Post Hoc test with respect to CONT. 
 
4.6. Effects of EST-related changes on outcome from lethal endotoxemia 
Mortality after lethal endotoxemia has previously been described to have 
strain specific differences (De Maio et al. 1998). A/J mice do not only have higher 
TNF-α levels and lower IL-10 plasma levels 1.5h after the injection of a lethal dose 
of LPS (15mg/kg), they also have a better survival rate (63% vs. 30% at 48h after the 
injection) (De Maio et al. 1998). Thus, we had to determine whether the changes in 
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cytokine patterns observed after EST-treatment would alter the outcome. Frequency 
of mortality was compared between non-operated mice (CONT) and mice that were 
castrated and supplemented with EST or placebo (VEH). After 48h, no difference in 
mortality was observed between non-operated and vehicle treated B6 mice (Survival: 
CONT 37%, VEH 36%). In contrast, castrated mice supplemented with EST showed 
an increased frequency of mortality (survival EST 8%). The data was obtained from 2 
independent experiments to assure reproducibility (Figure 10). 
Figure 10: Survival of estrogen-treated B6 male mice after injection of LPS. Male B6 
mice at the age of 6 weeks were castrated and treated with subcutaneous hormone pellets of 
17-β-estradiol (▲EST, n=27) or placebo (VEH, n=30). Non-castrated mice were used as 
control (♦CONT, n=30). Two weeks after the procedure, mice were injected with LPS 
(15mg/ml). All mice were maintained under the same environmental conditions. Survival was 
monitored over 48h, at this time-point survival was 8% for EST group, 36% for VEH group 
and 37% for CONT. The data represents the average mortalities from 2 independent 
experiments to assure reproducibility. Statistical significance was accepted at *p<0.05 
obtained with respect to CONT by using Fischer Exact Test. 
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Interestingly, castrated and VEH treated A/J mice had a markedly improved 
survival (90%) as compared to non-operated A/J males. Treatment with EST did not 
increase the frequency of mortality but seemed do enhance the velocity of LPS-
induced mortality in this strain. The data was obtained from 3 independent 
experiments to assure reproducibility (Figure 11). 
 
 
Figure 11 Survival of estrogen-treated A/J male mice after injection of LPS. Male A/J 
mice at the age of 6 weeks were castrated and treated with subcutaneous hormone pellets of 
17-β-estradiol (▲EST, n=44) or placebo (VEH, n=44). Non-castrated mice were used as 
control (♦CONT, n=44). Two weeks after the procedure, mice were injected with LPS 
(15mg/ml). All mice were maintained under the same environmental conditions. Survival 
was monitored over 48h, at this time-point survival was 16% for EST group, 90% for VEH 
group and 25% for CONT. The data represents the average mortalities from 3 independent 
experiments to assure reproducibility. Statistical significance was accepted at *p<0.05 
obtained with respect to CONT by using Fischer Exact Test. 
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Based on this data we determined if protection by androgen depletion could be 
found in other strains. AKR/J, BALB/cJ and DBA/2J were included into the 
experiment. Mice were castrated but no VEH pellets were implanted. In order to 
exclude the unlike possibility that VEH pellets would affect the outcome, additional 
A/J and B6 mice were enrolled into this series once again. Survival was monitored for 
up to 150h and compared to non-manipulated mice (CONT), which were maintained 
in an identical environment. Although provided by a different vendor, and 
consequently being exposed to different environmental conditions, C3H/HeN mice 
were also included. This strain has previously been reported to have improved 
survival after pharmacological castration in a model of trauma-hemorrhage with 
consequent sepsis (Angele et al. 1997). C3H/HeN are not identical with the LPS-
resistant strain C3H/HeJ provided by Jackson Laboratory. C3H/HeJ are hypo-
responsive to LPS because of a point-mutation in the cytoplasmatic domain of TLR-4 
and consequently lack signal-transduction (Poltorak et al. 1998). Over the time-
course of 150h, we found that A/J mice were the only strain that definitely benefited 
from removal of the testicles (Figure 12). This effect turned out to be independent of 
the application of the placebo pellet (Figure 11 and Figure 12a). The overall 
survival from castrated A/J mice in all experiments was 89% (50 of 56) as opposed to 
25% (11 of 56) in the non-operated groups. When additional castrated male A/J mice 
were supplemented with DHT pellets protection from LPS ceased (Figure 13).  
Frequency of mortality in all other strains remained unchanged, even in 
C3H/HeN (Figure 12c). For DBA/2J mice, the data may suggest attenuation of the 
dynamic of the clinical course, however without changing the outcome (Figure 12d). 
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Figure 12 a-f: Survival of castrated mice from different inbred strains after injection of LPS. 
Male A/J (Figure 12a), B6 (Figure 12b), C3H/HeN (Figure 12c), DBA/2J (Figure 12d), BALB/cJ 
(figure 12e) and AKR/J (Figure 12f) mice were castrated at the age of 6 weeks. Non-castrated mice 
were used as control and maintained under identical conditions. Two weeks after the procedure, mice 
were injected with LPS (15mg/ml). Survival was monitored up to 150h. Statistical significance was 
accepted at *p<0.05 obtained by comparison with respect to CONT by using Fischer Exact Test. 
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Figure 13: Survival of dihydrotestosterone-treated A/J male mice after injection of LPS. 
Male A/J mice were castrated (CX) at the age of 6 weeks and randomized into two groups. One 
group was treated with subcutaneous hormone pellets releasing 5-α-Dihydroxytestosterone 
( CX+DHT, n=15), the other group received no further hormonal treatment (CX, n=24). 
Non-castrated mice (●NOP, n=25) were used as control. Two weeks after the procedure, mice 
were injected with LPS (15mg/ml). Survival was monitored over 140h, at this time-point 
survival was 42% for CX group, 7% for CX+DHT group and 24% for CONT group. Statistical 
significance was accepted at *p<0.05 obtained with respect to CONT by using Fischer Exact 
Test. 
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5. DISCUSSION 
We have hypothesized that the response to injury is modified by three major factors: 
the type of injury, the environment and the genetic background (Figure 14). Prior 
studies in different experimental rodent models support this hypothesis (De Maio et 
al. 1998; Stewart et al. 2002; Trentzsch et al. 2003). This paradigm could explain the 
variability observed in the outcome of critically ill patients. In addition to these 
factors, gender is likely to be another component that influences the response to 
injury. 
 
 
Figure 14: The “Three-Circle-Theory”. This model considers determination of 
the inflammatory response as an intersection of three major components: The type 
of injury, the physical condition of the individual and its environment and the 
genetic make-up. As depicted here, the inflammatory response that can be 
measured after a certain injury such as injection of LPS can be understood as the 
hatched intersection of the three circles. 
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Clinical studies have shown that male septic patients have a higher risk of 
mortality with respect to the female counterpart (Schroder et al. 1998; Bauerle et al. 
2000; Schroder et al. 2000). However, these observations have been challenged by 
other studies that found no gender difference (Riche et al. 1996; Eachempati et al. 
1999; Wichmann et al. 2000), or an even higher mortality in septic female patients 
(McLauchlan et al. 1995; Napolitano et al. 2001; O'Keefe et al. 2001). A higher 
incidence of infection (Offner et al. 1999) and sepsis (McGowan et al. 1975) has also 
been associated with male patients.  In contrast, two other studies have shown a 
higher incidence of infection in female patients (Dinkel et al. 1994; Kollef et al. 
1997). In summary, there is no general consensus whether gender is a positive or 
negative factor in the outcome from injury. Genetic diversity may contribute to such 
contradicting results. However, genetic diversity has never really been considered in 
such studies. Only one study has so far suggested a gender-contribution on increased 
risk for mortality from sepsis associated with TNF-α polymorphisms (Schroder et al. 
2000). The contribution genetic variability of the inflammatory response in regard to 
sex-steroids however remains unconsidered so far. 
The importance of genetics in the response to injury has recently been 
demonstrated in animal models of endotoxemia (De Maio et al. 1998) and sepsis 
(Stewart et al. 2002). This genetic contribution has been evaluated at the level of 
mortality as well as at different components of the inflammatory process, such as 
cytokines (De Maio et al. 1998; Stewart et al. 2002), end-organ damage (O'Malley et 
al. 1998), and spleenocyte proliferation (Matesic et al. 1999). Clinical studies have 
been initiated to evaluate genetic components in sepsis research (Schroder et al. 2000; 
Tabrizi et al. 2001; Riese et al. 2003).The potential contribution of genetics to the 
inflammatory response became more important with completion of the Human 
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Genome Project. The sequencing data of the human genome revealed 1.42 million 
single nucleotide polymorphisms (SNP) within the 3 billion base pairs that built the 
whole human genome. This one tenth percent of differences implies that there are 3 
million possible differences between 2 individuals (Sachidanandam et al. 2001). Such 
genetic diversity provides solid bases for differences in the response to many 
pathological situations including sepsis. To evaluate the linkage between gender 
differences and their variability based on genetic differences, we have investigated 
this relationship in a model of endotoxemia in mice with dissimilar genetic 
background. Since these mice were subjected to the same insult and were maintained 
in an identical environment (Figure 14), the only variable that may account for such 
differences is the genetic background.  
 
5.1. Gender and genetics determine LPS-induced cytokine plasma levels through 
sex-steroidal modulation 
LPS-induced TNF-α plasma levels were different between male and female 
B6 mice indicating a gender-significant difference (Figure 2). By evaluating different 
stages of the estrus cycle in female B6 mice, our data suggests a hormonal bases for 
the observed gender difference. Surprisingly, we found that the estrus stage (high 
estrogen) was associated with rather depressed LPS-induced TNF-α levels, voiding 
the difference between male and female B6 mice, while females in di-estrus (low 
estrogen) displayed high TNF-α plasma levels that characterize this gender 
difference. With TNF-α playing a key role in induction of the inflammatory response, 
this observation might object the established dogma of a more active immune system 
in females. And moreover, estrogen has been described to increase TNF-α plasma 
levels after LPS challenge in female BALB/c mice (Zuckerman et al. 1995; 
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Zuckerman et al. 1996). However, decreased TNF-α expression and plasma levels 
after estrogen-treatment of female C3H/He mice has been found after inflammatory 
stimuli with protease peptone (Salem et al. 2000). These observations raise concern 
what effect estrogen actually has on TNF-α production and what differences between 
exogenous hormone treatment and physiological plasma levels exist. Actually, few 
data is available on estrogen-related effects on this cytokine throughout the estrus 
cycle and studies in humans remain controversial (Angstwurm et al. 1997; Schwarz et 
al. 2000; Bouman et al. 2001). 
The data on B6 mice clearly provides evidence for the hormone dependent 
modulation of the inflammatory response and thus implies gender-specific differences 
herein. Moreover, comparison with another strain of inbred mice (i.e. A/J) revealed 
that genetic diversity may have important impact on gender-differences in the 
inflammatory response and their modulation by sex-steroids: Although female A/J 
mice showed similar trends in the modulation of LPS-induced TNF-α plasma levels 
depending on the stage of the estrus cycle, there was no gender-difference detectable 
between male and female A/J mice (Figure 4), and androgen-depletion of male A/J 
mice did not change TNF-α plasma levels in the response to LPS injection (Table 1). 
Differences in hormone secretion, plasma protein binding, receptor affinity and 
density or hormone clearance and degradation may provide possible explanation for 
the variable qualitative and quantitative inflammatory response observed between 
these two strains. A number of such differences including plasma sex-steroid 
concentrations between various strains of inbred mice have been reported (Crispens 
1975). They are likely to be result of differences in the genetic composition of each 
strain. 
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To compensate for strain-differences in hormonal levels or cycle-dependant 
variability, mice were gonadectomized and supplemented with subcutaneous, 
constant release pellets of DHT or EST to deliver equal amounts of hormone into the 
mice. This model has previously been reported to result in physiologic hormone 
plasma levels in mice (Angele et al. 1999). Interestingly, no effect on TNF- α levels 
after hormone depletion by ovariectomy and VEH or ovariectomy with 
supplementation with EST or DHT was observed in either B6 or A/J female mice 
(Table 1). A similar observation has previously been made in humans, too. LPS-
induced TNF-α levels were increased by EST treatment of ex-vivo white blood cells 
(PBMC) from male volunteers while there was no effect in female PBMC (Asai et al. 
2001). It remains unclear, why females show this poor response to hormone 
manipulation. It may be the result of greater tolerance towards changes in sex-
hormone plasma levels that comes with cycle dependant fluctuation. Females may 
have differences in control and regulation of receptor-density as compared to males. 
It has been demonstrated that the endocrine modulation of the inflammatory response 
in rats is most likely to be controlled by the adrenal gland and may be dependant on 
the immune-reactivity of estrogen receptor α in the medullar cells (Green et al. 1999). 
Interestingly, administration of estriol (an estrogen agonist) to female 
BALB/c mice resulted in a dramatic increase in LPS-induced TNF-α levels 
approximately 1 hour after the injection. This increase was suppressed by 
administration of tamoxifen, an estrogen antagonist, (Zuckerman et al. 1996). Thus, 
females like BALB/c and by implication all other females with a genetic background 
other than B6 or A/J may be better responders to EST-treatment. 
The comparison of castrated and VEH treated or castrated and hormone 
treated male A/J and B6 mice revealed two important observations that clearly 
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support our hypothesis, that the genetic background may exert different effects on 
sex-steroidal modulation of the inflammatory response: First, depressive effects of 
androgens on LPS-induced TNF- α plasma levels were observed in B6 males only. 
Second, EST-treatment showed marked effects in males of either strain, however with 
opposite effects (Table 1). When other inbred strains (AKR/J, DBA/2J, and 
BALB/cJ) were included, it became apparent, that both observations are unique for 
B6 males (Table 2). Depressive effects of androgens on the inflammatory response 
have previously been described (Angele et al. 1997; Angele et al. 1998; Angele et al. 
1999). Androgen depletion by castration prevents this depression and can be reverted 
by pharmacological blockade of testosterone receptors with Flutamide (Angele et al. 
1997; Wichmann et al. 1997). Our studies showed that DHT-treatment was capable to 
reverse the effects of androgen depletion in castrated male B6 mice (Figure 13). 
After treatment with EST reduced TNF- α plasma levels after LPS injection 
were observed in male mice except from B6 males (Table 2). Data from female A/J 
and B6 mice in the estrus stage (high estrogen) of the cycle suggest similar tendencies 
in the effect of EST on LPS-induced TNF-α plasma levels (Figure 3 and Figure 4). 
Depression of LPS-induced TNF-α levels under the influence of EST has previously 
been observed. For example, peritoneal macrophages of 17-β-estradiol-treated 
C3H/He mice infected with Listeria monocytogenes show decreased gene expression 
and production of TNF-α (Salem et al. 1999). After treatment with estrogen, LPS-
induced TNF-α production of murine macrophages isolated from female BALB/c 
mice was reduced, possibly by interaction with NF-κB (Deshpande et al. 1997). 
However, data from the F1 generations bred from A/J and B6 mice suggests that the 
responsible alleles need to be homozygous (Table 5).  
 46
Our data suggests that the gender difference in TNF- α plasma levels after 
injection of LPS between B6 males and B6 females may be a result of differences in 
estrogen concentrations. EST treatment of males decreased LPS-induced TNF- α 
levels and plasma levels in estrus B6 females are comparable to males. Thus times of 
high estrogen blood levels seem to be responsible for the gender difference. 
Surprisingly, B6 females supplemented with EST after ovariectomie showed LPS-
induced TNF-α plasma levels comparable to those found in di-estrus B6 females and 
ovariectomized female B6 mice with VEH treatment (Mann-Whitney Rank Sum Test, 
p=0.807). Moreover, they also have higher TNF- α levels than male B6 mice 
(ANOVA on Ranks with Dunn’s correction, p<0.05). The amount of EST in the 
pellets may be very different from physiological 17-β-estradiol levels of naïve B6 
females in estrus. Sex-steroids are known to function within a broad range of 
concentrations but may have functional optimum at a specific dosage (Goretzlehner 
1991; Asai et al. 2001). Consequently, there may be dose-dependant variability in the 
capacity of sex-steroids to modulate the inflammatory response. By implication this 
includes strain-specific differences that are based on the genetic background. Thus, 
variable effects of sex steroids among inbred mice of different strains may also be a 
result of physiologic hormone plasma levels characteristic for each strain.  
Despite the lack of gender-differences in LPS-induced IL-10 plasma levels in 
B6 or A/J mice (Figure 5) hormonal modulation of the LPS-induced IL-10 response 
was suggested by stratification for different stages of the estrus cycle: In female A/J 
mice we observed a trend towards higher LPS-induced IL-10 plasma levels during 
estrus (high estrogen) as compared to diestrus (Figure 7). No such effect was 
observed in B6 females (Figure 6). Again, such differences may be explained by 
inter-strain variability. Further experiments revealed that LPS-induced IL-10 plasma 
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levels can be enhanced by EST-treatment in both sexes of either A/J or B6 mice 
(Table 3). While the TNF- α phenotype could not be reproduced in the F1-
Generations (Table 5), the effect of EST on LPS-induced IL-10 plasma levels could 
be observed in the F1-generations bred from A/J and B6 mice (Table 6). Castrated 
male AKR mice treated with EST also experienced an increase in LPS-induced IL-10 
levels (Table 4). The presence of steroid responsive elements in the promoter region 
of the IL-10 gene may provide a possible explanation for this finding (Kim et al. 
1992; Kube et al. 2001). However, the identified elements are not typical and 
functional assays have not been performed yet. Interestingly, two of the evaluated 
strains, i.e. DBA/2J and BALB/cJ, were identified as non-responders to EST 
treatment (Table 4). Estrogen responsive elements in the IL-10 promoter might be 
missing, be defective, or require a different dosage of EST for optimal function. 
Dose-dependency of hormonal effects has been described in humans (Goretzlehner 
1991; Asai et al. 2001) and may explain our finding in the LPS-induce TNF-α plasma 
levels of B6 mice. 
Regulatory pathways other than interaction of EST with the promoter of the 
IL-10 gene may be possible. For example, estrogen has also been reported to regulate 
IL-6 expression (Girasole et al. 1992; Deshpande et al. 1997), but to date, no estrogen 
responsive element has been detected in the IL-6 promoter (Ray et al. 1994; 
Deshpande et al. 1997). Indeed, the ability to decrease IL-6 levels has been related to 
direct interaction of estrogen with NF-κB (Ray et al. 1994; Stein et al. 1995). In 
conclusion, it is possible that sex-steroids regulated the inflammatory process at 
different levels. 
With respect to the effects of EST on LPS-induced IL-10 plasma levels, an 
alternative explanation for the TNF-α data come into view: Interleukin 10 down-
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regulates TNF-α expression and thus is responsible for a balancing effect on the 
proinflammatory response (Gerard et al. 1993; Marchant et al. 1994; van der Poll et 
al. 1997). However, there is evidence in our data that makes this scenario seem less 
likely: First, IL-10 plasma levels after LPS challenge are increased in castrated B6 
mice supplemented with EST. Consequently, a result of an inhibitory effect of IL-10 
should cause depression of TNF-α of these mice (Table 1). However, this observation 
may be explained by traits in the genetic background of the B6 strain. Actually, A/J 
and AKR/J do show decreased TNF-α levels along with increased IL-10 levels after 
EST treatment.  
Second, DBA/2J and BALB/cJ mice are unresponsive to EST-treatment and 
maintain the level of LPS-induced IL-10 levels (Table 4). However, LPS-induced 
TNF- α plasma levels also decrease with EST treatment in these two strains (Table 
2). There may be another regulatory mechanism involved in the down-regulation of 
TNF- α. It is also possible, that the unresponsiveness of DBA/2J and BALB/c mice 
actually is an artifact from sub-optimal dosage.  
Ovariectomized female A/J mice show an increase in LPS-induced IL-10 
plasma levels (Table 3). Apparently this does not match with the concept of IL-10 
modulation thru EST. It is however possible, that this finding is a consequence of 
regulation at an endocrine location other than the ovaries. Studies in rats suggest 
medullar cells in the adrenal gland to be responsible for gender differences in the 
inflammatory response (Green et al. 1999). 
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5.2. F1-generation: contribution of sex-chromosomes to TNF-α and IL-10 
phenotypes 
There are two possible mechanisms behind gender differences of any kind. 
One is a difference in hormonal activity, i.e. sex-steroids; the other is availability of 
alternative genetic information. In a genetic sense, sex-chromosomes are the only 
thing that make the difference between male and female (Passarge 1994): By looking 
at meiosis, it becomes clear, that apparently every single autosome is exchangeable 
between male and female without changing the genetic sex. However, the presence of 
an intact Y-chromosome will determine male sex of the embryo. Patients with two X 
chromosomes and an accessory Y-chromosome will clinically present with a male 
phenotype (Klinefelter-Syndrome), and individuals with only one X-chromosome will 
develop a female phenotype (Turner-Syndrome) as long as no Y-chromosome is 
present.  
Interestingly, the sex-determination is not dependant on the complete Y-
chromosome. The critical region that determines biologic sex lies on the distal short 
arm of the Y-chromosome. The physical map of this region shows the following 
subsets: The most distal part of the Y-chromosome is considered the 
pseudoautosomal region (PAR). Because of the homology with the distal part of the 
short arm of the X-chromosome homologue pairing and crossing-over may occur in 
this region of the Y-chromosome during meiosis - just like on any other autosome – 
without changing the sex.  
The adjacent region to PAR is segment 1. The total to a length of these two 
segments is 2500kb. The following segments 2 to 7 do not contain any relevant gene 
for male sex-determination. Located adjacent to PAR is the proximal part of segment 
1 (1 A1), were the sex-determining region Y (SRY) lays (Wolf et al. 1992). This 
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rather short sequence of just 35kb is most likely to be identical with the testis-
determinating factor (TDF). After transfection with the Sry-Region (the murine 14kb 
equivalent of the human SRY), transgenic mice with female genotype (X/X) will 
develop as males (Koopman et al. 1991). Similar sex-reversal as the result of an 
SRY-exchange by crossing-over during meiosis (a risk that comes with the close 
proximity of SRY to PAR) or secondary to a defective SRY through single nucleotide 
mutations have been described in humans (McElreavy et al. 1992; Wolf et al. 1992; 
Affara et al. 1993).  
Once the sex is determined genetically by sex-chromosomes, the development 
of each sex (sex-differentiation) can evolve. It is a complex, time-dependant process 
that requires the expression of a multitude of genes in different tissues. This gene-
expression is controlled by sex-hormones, like estrogen or testosterone. These 
hormones are primarily produced in the gonads. The presence of SYR initiates the 
development of testicles from the so far undifferentiated gonads. This step grants the 
production of high levels of androgens and thus causes differentiation of a male 
phenotype determined by a male genotype. In the absence of SRY the 
undifferentiated gonads will develop as ovaries (Ganong 1993).  
During sex-differentiation, sex-steroids are required as mediators to develop 
gender-specific features. The significance of the hormonal gene-regulation becomes 
apparent when the normal function is disturbed. For example, a defective testosterone 
receptor can cause testosterone-resistance. Despite a male genotype (X/Y), a female 
phenotype will evolve. This disorder is known as testicular feminism. The importance 
of estrogen in the female sex-differentiation is also illustrated in the adreno-genital 
syndrome (AGS). This disease is based on an estrogen-deficit caused by a defective 
21-hydroxilase. As a result metabolites of the estrogen-biosynthesis are shifted into 
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pathways of the androgen-production. The surplus in androgen hormones results in 
male features despite a female genotype (X/X) (Ganong 1993). 
Although the amount of DNA that actually makes the difference between 
male and female is very small, elucidation of the role of sex chromosomes in a study 
on genetic impact on gender differences of the inflammatory response is mandatory. 
Data on the TNF-α phenotype in F1 mice indicate that neither the gender 
difference in B6 mice nor the response to sex-steroids, in particular the modulation of 
the TNF-α by EST is linked to the sex-chromosomes or is genetically imprinted and 
requires homozygosity of the underling allele. Additionally, the opposite effects of 
EST on LPS-induced TNF-α levels may be the result of opposing alleles that may 
neutralize the parental phenotype in the F1-generation (Table 5).  
Data obtained from the F1 generation on the IL-10 phenotype may allow 
exclusion of any linkage to sex-chromosomes or imprinting, too. However, B X A 
respond like B6 only. Statistically there is no difference between A/J males and A x B 
or B6 males and A X B, respectively. A X B females follow the pattern of B6 mice, 
though. This may suggest a possible linkage to the A/J X-chromosome or maternal 
imprinting (Figure 9). The problem with this experiment however is that AxXxB mice 
are not commercially available and thus had to be bred in the institutional animal 
facility. Thus, a larger number of batches with a smaller number of animals per group 
were used per experiment. Consequently, environmental factors may differ from 
those for mice that were obtained from commercial sources, which may disturb the 
accuracy of this experiment. Moreover, female F1 mice were not stratified by stage of 
the estrus cycle, which may increase the variability in the control groups. 
A mapping approach currently under way suggests candidate genes located on 
chromosome 13 for the IL-10 phenotype in non-manipulated male mice after 
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injection of LPS and chromosome 9 for the TNF-α phenotype (unpublished data). 
However, the IL-10 gene is located on murine chromosome 1, the TNF-α gene is 
located on murine chromosome 17. In summary, the observed phenotypes in this 
study are very likely to follow a multi-factorial pattern of inheritance, involving a 
number of loci on different autosomes rather than to be linked to sex-chromosomes. 
Which loci significantly contribute to the observed effects of sex-steroids and 
gender-differences will have to be elucidated in future mapping approaches. 
Distribution of the TNF-α plasma levels after EST treatment in A/J and B6 males 
suggest that this phenotype may be suitable for comparative mapping strategies 
(Figure 15). Such concepts have previously been described (Matesic et al. 1999; 
Matesic et al. 2000). 
Besides sex steroids and sex chromosomes, other, yet unknown factors related 
to gender may be involved. Such factors have been suggested by the fact, that 
mortality due to infection is higher in newborn boys than in girls (Wells 2000). 
Additionally, a clinical study in burned children at an average age of 5 years reports a 
higher mortality rate in boys with respect to girls (Barrow et al. 1990). Sex-steroids 
obviously play a secondary role in these two populations. A comparable study on 
burns, in sexually mature adults, female sex was found as an independent risk-factor 
for adverse outcome (O'Keefe et al. 2001). Such contradicting results may correlate 
with gender differences independently of sex-steroids. 
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Figure 15: LPS-induced TNF-α plasma levels after estrogen-treatment in 
castrated A/J and B6 male mice. Mice underwent surgical castration by 
removal of their testicles at the age of 6 weeks. Subcutaneous constant release 
pellets containing 17-Estradiol (EST) were implanted. After 14 days of 
recovery, mice were injected with LPS (15mg/kg). TNF-α plasma levels 
(pg/ml) were measured 1.5h after the injection using an ELISA. Each dot 
represents the TNF-α plasma levels in each individual mouse in the respective 
group (A/J or B6). 
 
5.3. Protection from lethal endotoxic shock by castration depends on genetic 
background 
Androgen-depletion by surgical or pharmacological castration has been 
proposed to modulate the inflammatory response after hemorrhagic shock and 
improve outcome from subsequent sepsis (Wichmann et al. 1996; Angele et al. 1997; 
Angele et al. 1999). In analogy, female sex-steroids may have salutary effects to 
improved outcome (Zellweger et al. 1997; Angele et al. 2000; Knoferl et al. 2002). 
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Indeed, castrated A/J male mice were protected against lethal endotoxemic 
shock (Figure 12a). Survival was markedly improved over the evaluated time-course 
and restoration of the androgen hormonal environment by implantation of DHT 
pellets reversed this protection (Figure 13). In conclusion, androgen depletion results 
in protection from LPS. The most striking finding of our mortality-studies, however 
is that the benefit is restricted exclusively to the A/J genetic background. Castration 
may have decelerated the frequency of mortalities in DBA/2J mice though (Figure 
12d). All other examined strains had an unchanged outcome after surgical castration. 
C3H/HeN mice (Figure 12c) have been reported to have survival-benefits after 
androgen depletion in a model of abdominal sepsis following hemorrhagic shock 
(Angele et al. 1997). In our model, they showed no improved outcome. 
Consequently, protection by androgen depletion may not only depend on the genetic 
background but moreover may change with the type of injury. Qualitative and 
quantitative divergence in the response to different types of injury can be observed in 
animal models: CLP produces a quite different cytokine response as observed during 
endotoxemia (Villa et al. 1995; De Maio et al. 1998; Remick et al. 2000; Stewart et 
al. 2002). Variable extend of an injury influences the inflammatory response as 
demonstrated in a model of combined insult using CLP and endotoxic shock 
(Trentzsch et al. 2003). 
A mechanistic explanation for protection through androgen depletion has not 
yet been provided. The evaluated cytokines may suggest reduced TNF-α plasma 
levels and increased IL-10 plasma levels in A/J male mice after castration as a 
possible explanation. This observation may suggest a shift in the ratio of pro- vs. anti-
inflammatory activity. Although, the cytokine levels lack statistical significance, the 
analysis of the TNF/IL-10 ratio of these mice indicates a significant drop (Table 7a) 
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suggesting attenuation of the predominantly pro-inflammatory state towards an anti-
inflammatory state. EST-treatment of A/J males after castration also results in a 
decrease of TNF-α and an increase of IL-10 plasma levels. Indeed, the TNF/IL-10 
ratio is diminished even further and thus the inflammatory response is changed from a 
predominantly pro-inflammatory response towards an anti-inflammatory state (Table 
7b). Interestingly, this was not associated with improved survival and actually 
accelerated the clinical course, although the outcome after all was unchanged (Figure 
11).  
Improved survival may depend on the ideal equilibrium of pro- and anti-
inflammatory components of the inflammatory response. Pharmacological approaches 
to attenuated sepsis in order to improve survival of septic patients aim at anti-
inflammatory strategies. The latest promising candidates for “magic bullets”1 are 
Afelimomab, a new F(ab`)2 antibody fragment against TNF-α; and activated protein 
C (Xigirs™), which actually possesses anti-inflammatory properties by inhibiting the 
LPS-induced liberation of TNF-α (Bloos et al. 2002; Hotchkiss et al. 2003). However, 
these adjuncts are restricted to the early phase of sepsis and thus illustrate the delicacy 
of the pro-/anti-inflammatory equilibrium that is mandatory for survival from sepsis. 
Overwhelming anti-inflammatory predominance may cause depression of the cellular 
immune function and consequently predispose to increased risk of infectious 
complication, most likely to result in a fatal course (Faist et al. 1996; Oberholzer et al. 
2002).  
Testosterone blockage with Flutamide protected male C3H/HeN mice from 
septic insults after hemorrhagic shock (Angele et al. 1997). In a number of clinical 
                                                 
1 A fundamental concept of modern pharmacology is that each pathologic condition can be corrected or 
reversed by a single pharmacological compound. Paul Ehrlich, who first enunciated this concept, called 
such compounds “magic bullets”.  
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studies, a decrease of testosterone levels has been described in male patients after 
burns (Lephart et al. 1987), trauma (Majetschak et al. 2000), and sepsis or  septic 
shock (Christeff et al. 1988; Christeff et al. 1992; Fourrier et al. 1994; Schroder et al. 
1998). Assuming that low testosterone may offer protection from injury, this response 
may be interpreted as a possible strategy of the organism to adapt to stressful 
conditions. Surprisingly, this decrease has been reported to be accompanied by an 
increase in estrogen levels, (Benassayag et al. 1984; Christeff et al. 1988; Christeff et  
al. 1992; Fourrier et al. 1994; Schroder et al. 1998; Majetschak et al. 2000) and two 
clinical studies  report increased mortality among male patients with such hormonal 
changes (Schroder et al. 1998; Majetschak et al. 2000). However, testosterone 
concentrations in severely ill male patients inversely correlated with APACHE scores 
(Luppa et al. 1991), implying that severely ill patients with high testosterone levels 
have low APACHE score and thus have a better likely-hood to survive. Taking our 
mortality studies in castrated male mice into consideration, such contradictive 
findings may be explained by genetic differences in the studied cohort’s gene-pool. 
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Table 7a+b : Effects of castration on the TNF-α/IL-10 ratio in male mice. Male mice 
were castrated (CX) and supplemented with vehicle pellets (VEH) at the age of 6 weeks. 
After recovery for 14 days, LPS was injected (15mg/kg). Blood samples were obtained upon 
sacrifice 1.5h after the injection and TNF-α and IL-10 plasma levels were measured using an 
ELISA. Non-operated mice of each strain were maintained under identical conditions and 
used as control (CONT).  Table 7a shows baseline ratios of the “inflammatory 
coefficient” (i.e. ratio of TNF-α/IL-10) of mice from various inbred strains (AKR/J n=8; A/J 
n=31; B6 n=32; BALB/cJ n=10; and DBA/2J n=7) in comparison with ratios of mice after 
surgical castration and implantation of vehicle pellets (CX+VEH: AKR/J n=7; A/J n=21; B6 
n=15; BALB/cJ n=9; and DBA/2J n=8). Data corresponds to the average ratio obtained from 
all animals in the group ± standard error of the mean. Statistical significance was accepted at 
*p< 0.05 obtained by Mann-Whitney-Rank Sum Test.  Table 7 b shows changes in TNF-
α/IL-10 ratio in male A/J mice after castration and hormonal treatment. Mice were treated as 
described. Additional males were castrated (CX) and supplemented with hormone pellets 
(DHT, n=22; EST, n=19). Data corresponds to the average TNF-α/IL-10 ratio obtained from 
all animals in the group ± standard error of the mean. Statistical significance was accepted at 
*p< 0.05 obtained by Mann-Whitney Rank Sum Test for pair-wise comparison VEH vs. 
CONT and #p<0.05 for pair-wise comparison EST vs. VEH. 
Table 7a AKR/J A/J B6 BALB/cJ DBA/2J 
 2.3 ±0.4 3.2 ±0.4 0.8 ±0.1 0.9 ±0.2 9.4 ±1.6 
CONT n= 8 n= 31 n= 32 n= 10 n= 7 
      
 1.6 ±0.1 1.7 ±0.4 1.2 ±0.2 1.0 ±0.3 8.8 ±1.5 
CX 
(+VEH) n= 7 n= 21 n= 15 n= 9 n= 8 
 p= 0.173 p= 0.004* p= 0.182 p= 0.967 p= 0.397 
Table 7b CONT CX +VEH CX +DHT CX +EST 
 3.2 ±0.4 1.7 ±0.4 4.2 ±1.5 0.5 ±0.1 
A/J n= 31 n= 21 n= 22 n= 19 
  p= 0.004* p= 0.179 p< 0.001*# 
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5.4. Critical effects of EST on LPS-induced mortality 
Modulation of the inflammatory response during endotoxemia in EST-treated 
male B6 mice increased mortality significantly (Figure 10). This finding contradicts 
with the idea, as concluded from many studies, that female rodents have better 
survival than males after injury as a result of sex-steroids (Zellweger et al. 1997; 
Angele et al. 2000; Diodato et al. 2001; Knoferl et al. 2002). Interestingly, no 
differences in mortality between female and male B6 mice after injection of LPS have 
been observed (Laubach et al. 1998). Since the genetic background seems responsible 
for gender differences and sex-steroidal modulation of the inflammatory response, B6 
may not have a suitable make-up for showing gender differences in outcome and 
inflammatory response in a model of endotoxemia. This strain may also be more 
susceptible to adverse effects of EST. Activated CD4+ T-cells (helper T-cells) secrete 
cytokines with either one of two distinct and antagonistic profiles. They secrete either 
cytokines with inflammatory properties (type 1 helper T-cell; Th-1) including TNF-α, 
IFN- γ, and interleukin 2, or cytokines with anti-inflammatory properties (type 2 
helper T-cells ; Th-2), such as interleukin 4 and IL-10 (Abbas et al. 1996; Opal et al. 
2000). The Th-1 response plays a role in activation and recruitment of other T-cells 
and macrophages; the Th-2 response regulates antibody secretion from B-cells and 
exerts anti-inflammatory properties via IL-10. Th-1 and Th-2 clones are reciprocally 
regulated by their secreted cytokines: INF- γ inhibits the proliferation of Th-2 clones 
whereas IL-10 inhibits that of Th1 clones (Giron-Gonzalez et al. 2000). A shift in the 
T-cell function towards Th-2 is believed to play a key role in cell-mediated immune 
dysfunction after trauma and critical illness, which is associated with an increased 
risk of septic complications (Faist et al. 1996; Hotchkiss et al. 2003). Such changes in 
T-cell function have been demonstrated in humans after burns (Zedler et al. 1999) 
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and abdominal sepsis (Heidecke et al. 2000). A similar shift from Th-1 to Th-2 type 
response has also been observed in animal models of trauma hemorrhage (Ayala et al. 
1996; Schneider et al. 2000). Interestingly, estrogen enhances phospholipase A2 
activity and consequently increases prostaglandin production (Dey et al. 1982). 
Production of prostaglandin E2 from monocytes promotes the described shift in T-
cell function from Th-1 to Th-2 (Faist et al. 1996). Based on this concept, estrogen 
may be rather fatal than beneficial in septic patients. Indeed, an increase in estrogen 
levels can be observed in such patients (Benassayag et al. 1984; Christeff et al. 1988; 
Christeff et al. 1992; Fourrier et al. 1994; Schroder et al. 1998; Majetschak et al. 
2000). The increase in plasma estrogen levels is accompanied by decreasing 
testosterone levels and as observed in two clinical studies (Schroder et al. 1998; 
Majetschak et al. 2000) this finding correlates with increased mortality associated 
with male gender. A state of high estrogen and low testosterone reflects conditions 
similar to those in our mortality study and thus may explain the severe effects of 
EST-treatment on castrated B6 males (Figure 10). High estrogen plasma levels may 
contribute to the shift in T-cell function that is associated with posttraumatic immune 
changes. As studies in humans may suggest, the major sex-dimorphic difference in 
the inflammatory response is a predominantly Th-2 biased response in females as 
opposed to a predominantly Th-1 response in males (Giron-Gonzalez et al. 2000). 
This situation is likely to be determined by estrogen-action. Estrogen-treatment 
promotes suppression of the Th-1 type response in the delayed-type hypersensitivity 
response to purified protein derivatives in mice (Salem et al. 2000). We have 
observed markedly increased IL-10 plasma levels after EST-treatment in several 
strains of inbred mice (Table 3 and Table 4). Interleukin 10 is a defining cytokine of 
the Th-2 response (Faist et al. 1996) and has been shown to down-regulate the 
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production of several pro-inflammatory cytokines, including TNF-α, IL-1, IL-6, IL-
12 and IL-18 (Moore et al. 1993). However, the beneficial effect of IL-10 in the 
response to injury is controversial. Exogenously administration of IL-10 has been 
shown to reduce several aspects of the inflammatory process and improve survival in 
experimental models of endotoxemia (Howard et al. 1993) and against staphylococcal 
enterotoxin B (Bean et al. 1993). On the other hand, similar experiments in animal 
models of sepsis and thermal injury have shown no effect on inflammatory mediators, 
increased T-cell dysfunction, and elevated mortality (Oberholzer et al. 2002). Further 
studies will have to determine whether EST can be helpful to modulate the 
inflammatory response in order to protect from adverse outcome after injury. Correct 
dosage might be of critical importance (Goretzlehner 1991) and so may be the right 
equilibrium between androgen and estrogens (Angele et al. 1998). However, the 
genetic background and type of injury may restrict such approach to an exclusive 
group of patients. In our model, we were not able to identify such a group within the 
evaluated gene-pool. 
 
5.5. Clinical and scientific relevance of the findings 
Our findings illustrate, that the modulation of the inflammatory response by 
sex-steroids depends on the genetic make-up of the subject. During sex-
differentiation, sex-steroids control the expression of genes that are responsible for 
the formation of gender-specific features. Studies suggest that genes encoding 
mediators of the inflammatory response are under sex-steroidal control: Estrogen 
receptors (ERs) have been identified in the nuclei of various human immune cells, 
such as monocytes (Wada et al. 1992; Ben-Hur et al. 1995), macrophages (Gulshan et 
al. 1990), and T cells(Cohen et al. 1983; Cutolo et al. 1993). There is evidence of 
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membrane-bound ERs on the surface of monocytes (Stefano et al. 1999). Steroid 
responsive elements are located in the promoter region of the IL-10 gene (Kim et al. 
1992; Kube et al. 2001). Estrogen may possibly control cytokine production by direct 
interaction with NF-κB (Ray et al. 1994; Stein et al. 1995). Apparently, sex-steroids 
regulate the inflammatory process at different levels and all of these mechanisms 
offer a vast number of possible genetic differences.  
However, the effect of sex-steroids on the inflammatory response is not 
heterogeneous: A decrease in LPS-induced production of TNF-α was observed in 
murine splenic macrophages from BALB/c mice treated with EST (Deshpande et al. 
1997). In contrast, an increase in this cytokine was observed in peritoneal 
macrophages derived from female BALB/c mice (Zuckerman et al. 1996), or male 
rats (Chao et al. 1994) both treated with LPS and EST. A reduction in IL-6 levels was 
found in BALB/c splenic macrophages treated with LPS and EST (Deshpande et al. 
1997), which is the opposite observation as in peritoneal macrophages from female 
BALB/c mice under similar conditions (Zuckerman et al. 1996). While these findings 
may indicate different responses in distinct compartments of the inflammatory 
cascade and thus may contribute to the contradicting results, our data clearly 
demonstrates that the genetic background determines variable modulation of the 
inflammatory response by sex-steroids. This genetic component can be easily 
visualized by analyzing the ratio between IL-10 and TNF-α of each strain (Figure 16 
a + b). Changes in this ratio by administration of EST are obviously very different 
and predicting the effect seems impossible. 
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Figure 16 a+b: Strain-specific variability in TNF/IL-10 ratio of male mice 1.5h after 
injection of LPS. Figure 16a shows the distribution of average TNF/IL-10 ratios of non-
manipulated, 8 week old male mice after injection of LPS (15mg/kg). AKR n= 8, A/J n=10, B6 
n=6, BALB/c n=10, DBA/2J n=7. Figure 16b additionally shows the distribution of TNF/Il-10 
ratio in male mice that were castrated at the age of 6 weeks and received EST-treatment for 2 
weeks. Arrows indicate the shift in the ratio that resulted from the EST-treatment. AKR (n=8), 
A/J (n=7), B6 (n=6), BALB/c (n=8), DBA/2J (n=8). Each dot represents the average TNF/IL-
10 ratio of each group. Arrows indicate the shift in the ratio when compared with non-
manipulated CONT. 
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We are aware, that findings in mice are difficult to be extrapolated to men. However, 
our observations suggest a critical role of hormones and hormonal treatment in 
critically ill patients. Sex steroids are routinely employed in the clinical field, for 
example in prostate cancer therapy and hormone replacement therapy (HRT). 
Consequently, information on how hormones influence the body’s homeostasis is of 
importance. This became illustrated most recently by the confusion caused by the halt 
of the estrogen plus progestin (Prempro™) component in the Women’s Health 
Initiative (WHI), a randomized, placebo-controlled and blinded, multi-center trail 
enrolling 27.348 patients for evaluation of HRT. As a matter of fact, 22.3 million 
prescriptions make Prempro™ the second most frequently prescribed hormone 
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replacement medication throughout the US in 2000 (Kreling et al. 2001). The data 
and safety monitoring board (DSMB) of the WHI made their recommendation to halt 
the Prempro™ treatment-arm, after Prempro™ medication was associated with an 
increased risk of invasive breast cancer, stroke, coronary heart disease, and 
pulmonary embolism. An overall measurement suggested that HRT with estrogen 
plus progestin would do more harm than good (i.e. reduced risk of colorectal cancer 
and reduced hip-fractures) (Fletcher et al. 2002; Rossouw et al. 2002). As a result of 
the DSMB-recommendation, physicians worldwide had to wonder if HRT could be 
considered safe. Epidemiologic data of the WHI indicates that the majority of patients 
enrolled in this trail were Caucasians. One may speculate if the increased risk would 
have been reduced, if patients with potential genetic risk-factors would have been 
excluded.  
In another study on men after coronary artery bypass found reduced leukocyte 
activation after estrogen treatment which may contribute to improved graft survival 
(Wei et al. 2001). However, the sample size was too small to detect improved 
outcome and there were no significant changes in cytokine profiles. If they 
successfully prevented sepsis and multiple organ failure was not evaluated. 
Apparently, EST-treatment was tolerated better than in our model. This may be a 
result of the type of injury, differences in environmental factors, or genetics 
(including genetic differences between species!). 
Our data supports the hypothesis that clinical application of sex-steroids or 
alteration of sex-hormone profiles in critically ill patients may be difficult to asses 
without consideration of the genetic background. Quantitative trait loci that are 
responsible for the phenotypes observed in our mouse model may have homologies in 
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the human genome and thus one day may allow identification of patients at risk to 
develop sepsis or to adjust their therapeutic regiments. 
Preliminary sequencing data from the human genome project reveals that the 
human genome consists of possibly 25,000 to 40,000 genes. Only twice as many as in 
fruit fly, worm, or plant and about the same number of genes that built the murine 
genome (Waterston et al. 2002). 
Genomics, the science of determining the functions of individual gene 
segments, facilitates structural homologies between evolutionarily, closely related 
genomes. Its success is based on a simple concept: Functionally important sequences 
are more likely to retain their sequence during evolution than non-functional 
sequences. So DNA sequences that are conserved between species are likely to have 
important function. Comparison of genomes of closely related species may also help 
to identify gene-control regions (Rubin 2001). We may assume that homologies of 
loci that control the inflammatory response between mice and men exist. An 
assumption that has been fueled by disclosure of sequencing data of the murine 
genome (Waterston et al. 2002). 
 
5.6. Comments on methodology 
We have based our experimental approach to the role genetic contribution to 
sex-steroidal modulation of the inflammatory response on the premises that the 
inflammatory response is the intersection of three major components: type of injury, 
environmental factors and the genetic background (Figure 14). To disclose 
differences that are determined by either one of these three factors, uncompromised 
experimental control of the other factors is mandatory. In our model, we studied the 
inflammatory response induced by injection of LPS to inbred mice. The use of small 
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rodents provides a lot of advantages. They are inexpensive, widely available in large 
numbers, at the same age and sex, genetically identical, free of specific pathogens, 
and on the same diet, which minimize biological variability. 
LPS-models are well-know for their reliable and reproducible results 
(Chaudry 1999). TLR4 seems to be the sole gateway to the LPS-induce inflammatory 
response in mice, by implication in all mammals. LPS itself is not capable to evoke 
shock, tissue injury, and other effects through non-specific interaction. Instead it can 
be anticipated that these effects are a product of the pro-inflammatory cascade 
activated by this single pathway (Beutler et al. 2001). Highly reproducible 
phenotypes are the fundamental bases for comparative mapping-strategies. LPS-
injections require only minimal animal manipulation and thus warrant little alteration 
of the organism’s homeostasis after the inflammatory challenge. Our experience with 
the LPS-model reassures us that observations in this model are highly reproducible 
(De Maio et al. 1998).  
Apparently, gram-negative sepsis can not be restricted to LPS alone. 
Consequently, experimental endotoxemia is probably a better model of inflammation 
and acute phase response than of authentic sepsis. However, we think that the early 
events of the acute phase and inflammatory response are key-factors in the 
pathogenesis of sepsis and the resulting clinical course. Endotoxic shock provides an 
excellent model to study the impact of the genetic background on the inflammatory 
response because it reduces the risk of other pathways creating too much background, 
which actually may mask genetic differences. 
Many LPS preparations are contaminated with other bacterial products 
reacting with different Toll receptors, which may explain some of the discrepancies in 
the literature with regard to LPS (Hirschfeld et al. 2000). Although a non-extracted 
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mixture might represent real biology, it complicates experimentation. Only when LPS 
is re-extracted it acts as a pure TLR4 activator. To keep the experimental conditions 
in this study constant, we utilized LPS from a single batch only. 
LPS produces a cytokine-rich inflammatory response. To quantify the 
inflammatory response and to detect changes in the response after hormone 
manipulation, we selected two of the possible markers involved, TNF-α and IL-10. 
These two markers have been considered as major players of the LPS-induced 
inflammatory response. A large body of evidence on these two markers has been 
accumulated, providing a broad basis for discussion of the findings. Detection by the 
use of ELISA-Kits is state of the art (Ertel et al. 1993). 
Studying hormonal effects is a big experimental challenge. Endocrine activity 
underlies dynamic changes that lie beyond experimental control or simply exceed a 
practical approach. Obviously the biggest challenge in studies on sex-hormones is the 
reproductive cycle of females that is accompanied with a load of hormonal changes 
over a short period of time. As outlined in Appendix 1, the window of a certain 
condition may close over the time-course of an experiment and thus complicates 
experimental conditions (e.g. mortality-studies). Moreover, misinterpretation of 
smears may occur (e.g. anestrus or pseudopregnancy). For example, cycle-related 
changes on cytokine, such as TNF-α in humans remains controversial (Angstwurm et 
al. 1997; Schwarz et al. 2000; Bouman et al. 2001). The evaluation of cycle-
determined differences is complicated and difficult to perform even in the controlled 
environment of an animal model. For this reason and to control for strain-specific 
differences in hormonal features, we decided to control hormonal activities by 
applying defined doses of hormone into gonadectomized animals. This model has 
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previously been reported to result in physiologic hormone plasma levels in mice 
(Angele et al. 1999). 
Administration of LPS and estriol (an estrogen agonist) to female BALB/c 
mice did not affect IL-6 serum levels, but did change the kinetics of its appearance in 
the circulation (Zuckerman et al. 1996). We did not check for changes in the kinetics 
of our model. It is possible that IL-10 plasma levels in DBA/2J and BALB/cJ mice 
after EST treatment reached peaks either before or after our designated time-point 
that we may have missed. This may explain why we did not see any response to DHT 
and why female mice seemed to be unresponsive to hormonal manipulation. 
However, we feel comfortable with this decision, since changes in the kinetics may 
be result of strain-specific traits and thus would be referred to as a result of different 
genetics. However such changes would not be suitable as map-able phenotypes and 
therefore are of minor interest. 
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6. SUMMARY 
We have shown that gender is a contributing factor in the LPS-induced inflammatory 
response of B6 mice. Gender-dimorphisms of the inflammatory response appear to be 
associated with hormonal differences. However, this contribution is dependent on the 
genetic background, as demonstrated in comparison with A/J mice. Additionally, we 
found that treatment with sex-steroid modulates LPS-induced mediators of the 
inflammatory response, such as IL-10 and TNF-α. However, male mice seem to be 
better responders to such manipulation. Moreover, the effects were dependent on 
genetic differences. Some mouse strains revealed to be non-responders to changes in 
the hormonal environment, i.e. IL-10 levels after EST-treatment in DBA2/J and 
BALBc/J mice, while others showed opposing response, i.e. TNF-α levels of EST-
treated A/J and B6 mice. Thus, our data suggests that gender and genetic diversity 
combine to modulate the response to a particular injury. However, the effects of sex-
steroids and the observed gender-differences seem to be independent of sex-
chromosomes. We also evaluated effects of hormonal manipulation at the levels of 
mortality. Androgen depletion is considered a mainstay of gender-related differences 
and may improve survival. Interestingly, castration protected only A/J mice against 
LPS. Such protective effects may be secondary to sex-steroid controlled changes in 
the ratio of pro- vs. anti-inflammatory components of the inflammatory cascade. 
However, we concluded that protection is dependent on the type of injury and the 
genetic background. EST-treatment of A/J and B6 males did not improve outcome 
from endotoxic shock.  
If our findings in mice could be extrapolated to humans, they might explain 
contradictory observations of clinical studies on gender differences. Genetic markers 
might better delineate the contribution of gender in the response to injury in the 
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clinical setting. Thus, research on such markers needs to be intensified in the future. 
Consequently, this information is of importance for planning basic science 
experiments, clinical trials and for the development of therapies that ameliorate the 
secondary effects of injury.  
 
7. ZUSAMMENFASSUNG 
Die hier vorliegenden Daten zeigen deutliche geschlechtsspezifische Unterschiede in 
der LPS-induzierten entzündlichen Antwort von B6-Mäusen. Geschlechtsspezifische 
Dimorphismen der entzündlichen Antwort scheinen mit hormonell bedingten 
Unterschieden assoziiert zu sein. Der Vergleich mit A/J-Mäusen weist hierbei jedoch 
eine unterschiedliche Ausprägung in Abhängigkeit von genetischen Faktoren auf. 
Darüber hinaus wurde festgestellt, dass die hier untersuchten Marker TNF-α und IL-
10 durch Behandlung mit Sexual-Steroiden moduliert werden können. Männliche 
Tiere reagieren dabei allerdings deutlich besser auf diese Beeinflussung von außen. 
Auch hier wurde eine Abhängigkeit von genetischen Faktoren gezeigt: Einige der 
untersuchten Mausstämme erwiesen sich von den Veränderungen der hormonellen 
Bedingungen unbeeinflusst, wie an den IL-10 Plasmaspiegel von DBA2/J und 
BALBc/J Mäusen nach EST-Behandlung zu sehen ist, während andere Stämme gar 
gegensätzliche Antworten zeigten, wie an den TNF-α Plasmaspiegeln nach EST-
Behandlung von A/J und B6 Mäusen erkennbar wird. 
Somit erlauben die vorgelegten Daten die Schlussfolgerung, dass biologisches 
Geschlecht und individuelle genetische Ausstattung gemeinsam einen messbaren 
Einfluss auf die entzündliche Antwort nach einer bestimmten Verletzung haben. Die 
Effekte von Sexualsteroiden und Geschlechtsunterschieden sind dabei unabhängig 
von den Geschlechtschromosomen. Da Androgene allgemein als hauptsächlich 
 71
verantwortlich für die geschlechtsspezifischen Unterschiede der entzündlichen 
Antwort eingeschätzt werden, haben wir von der Verringerung der systemischen 
Androgenspiegel einen Überlebensvorteil erwartet. Um so interessanter war die 
Beobachtung, dass diesbezüglich lediglich A/J Mäuse nach chirurgischer Kastration 
vor den Auswirkungen der LPS-Gabe geschützt waren. Dieser protektive Effekt 
könnte die Folge von sexual-steroid-abhängigen Änderungen in der Relation von pro- 
und antiinflammatorischer Komponente der entzündlichen Antwort sein. Es ist 
anzunehmen, dass dieser Schutz nur bei entsprechender genetischer Konstellation und 
wahrscheinlich in Abhängigkeit vom Verletzungsmechanismus zustande kommt. 
EST-Behandlung von männlichen A/J and B6 Mäusen brachte kein verbessertes 
Überleben nach Endotoxinschock. 
Könnte man diese Ergebnisse auf Menschen übertragen, so ließe sich hieraus 
eine Erklärung für gegensätzliche Beobachtungen bei geschlechtsspezifischen 
Unterschieden in klinischen Studien ableiten. Genetische Marker könnten helfen, die 
Einflüsse des biologischen Geschlechts auf die entzündliche Antwort klinisch besser 
untersuchen zu können. Die Suche nach solchen Markern sollte in Zukunft 
intensiviert werden, da ihnen auch eine große Bedeutung für das Design von 
Laborexperimenten und klinischen Studien zukommt, aus denen sich dann eventuell 
sogar therapeutische Ansätzen zur Milderung der sekundären Effekte von 
Verletzungen ableiten lassen. 
 72
APPENDIX 1: On the Estrus Cycle of the Mouse. 
 
Female mice have a poly-estrus cycle that persists throughout the whole year. 
Central endocrine regulation involves Gonadotrophine Releasing Hormone (GnRH), 
Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) that are derived 
from hypothalamus and piturity gland and control levels of estradiol and 
progesterone, which themselves contribute to the regulation of the estrus cycle 
through positive feed-back mechanism on the central regulation. The ovaries are the 
major source of estradiol and progesterone. The growing oocyte produces estradiol. 
Throughout the cycle, phases of predominant estradiol-levels or predominant 
progesterone-levels create four stage of the estrus cycle: diestrus, proestrus, estrus 
and metestrus (also know as postestrus or metaestrus; subdivision into phase I and II 
may occur). The estradiol/progesterone-ratio changes over these stages (Nelson et al. 
1981). Consequently, metabolic changes occur along the cycle: Proestrus and estrus 
are anabolic stages with active growth, whereas metestrus is a catabolic stage of 
degenerative changes. Diestrus is a quiescent stage with slow growth (Schwacha et al. 
2001). Morphologic changes in the cells reflect these metabolic changes. There are 
three types of cells commonly found in smears obtained from the vagina: 
Polymorphonuclear cells (i.e. leucocytes), nucleated epithelium cells and cornified 
epithelium cells. The morphology and number of these three types reflects the phase 
of the cycle and has been well described (Barkley et al. 1981; Rugh 1990; Schwacha 
et al. 2001): 
Peak levels of estrogen characterize proestrus (20-25 pg/ml in CD-1 mice 
(Campbell et al. 1976) and CBA/J NIA mice (Kahlke et al. 2000); up to 28 pg/ml in 
B6 (Nelson et al. 1981)). Smears show approximately even numbers of leucocytes 
and primarily nucleated epithelium cells. Only few cornified cells are present. This 
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phase takes 24 to 36h. While estradiol-levels start to decline with the onset of estrus, 
progesterone starts to increase. The epithelium cells of the vagina show an 
accelerated turnover. A lot of huge, squamous, cornified cells without nuclei are 
obtained in the smear. Leukocytes are missing completely. In the early phase of 
estrus, clearly defined epithelial cells with distinct nuclei can also be found. Estrus, 
(from Greek oestrum for “heat”) is the beginning of the reproductive state in the 
cycle. Ovulation starts 2 to 3 hours after the onset of estrus (Crispens 1975). 
However, it is the shortest phase of all and takes only 12 to 14h (Crispens 1975). 
Extended duration of estrus up to 72h has been described (Schwacha et al. 2001). 
Throughout metestrus, estrogen-levels further decline (as low as 5 pg/ml in CD-1 
mice (Campbell et al. 1976)) and progesterone-levels remain high (9.9 ng/ml have 
been described on day 0 of pregnancy (Crispens 1975), which is comparable to 
maximum progesterone levels during metestrus in CD-1 mice (Campbell et al. 1976), 
slightly lower levels of 4 ng/ml were found in B6 (Nelson et al. 1981)). Now, the 
epithelium cells are large, folded and with translucent nuclei. They lie in even 
numbers with leucocytes. This phase takes 24 to 48h (Crispens 1975) but can extend 
up to 120h (Schwacha et al. 2001). Diestrus starts as progesterone-levels go back to 
baseline (~2 ng/ml progesterone during proestrus (Campbell et al. 1976; Nelson et al. 
1981)). Estradiol remains low. The smear will now produce almost exclusively 
leukocytes. This phase takes 36 to 72h before rising estradiol levels lead into a new 
onset of proestrus. Under certain conditions, diestrus is prolonged for several days. 
An easy way to determine the stage of the estrus cyle is to obtain smears 
through lavage with isotonic saline solution as described by Rugh (Rugh 1990). An 
alternative technique is inspection of the typical changes found in the genital by 
Champlin (Champlin et al. 1973). While this technique is less invasive than a lavage, 
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which is considered a low-stress procedure anyhow, inspection demands a lot of 
experience in order to make valid predictions on the stage of the cycle. However, it 
may be preferable for repeated sampling. Repeated smearing, especially with cotton 
swabs is likely to result in vaginal cornification or the induction of 
pseudopregnancy. 
The duration of the cycle has an average duration of 4 to 5 days, however 
most authors report variable length of the different phases. The total of days may 
exceed this period and thus cycle length varies between 3 to 9 days. In fact, regularly 
recurring cycles are rare in the mouse other than in rats (Barkley et al. 1981). Several 
factors have impact on the estrus cycle: day-night-phases (Campbell et al. 1976), age 
(Nelson et al. 1981) and even genetic background (Barkley et al. 1981) influence its 
delicate dynamics. CF-1 female mice subjected to short-term food deprivation (24h or 
48h) showed delay of ovulation by a week or more when 48 h of food deprivation 
was initiated in diestrus. Lesser delays occurred when food deprivation began in 
estrus (Bronson et al. 1985). 
The absence of males or housing large groups of females together in the same 
cage may result in irregular cycling (i.e. prolonged diestrus). Two different types 
can be distinguished: anestrus or pseudopregnancy. Anestrus is characterized by 
prolonged diestrus predominantly when large groups of females are housed together 
and rapidly changes to estrus upon pairing with males. Pseudopregnancy shows 
formation of deciduomata and occurs preferablely in small groups of females without 
presence of males. For both phenomena, a genetic contribution has been suggested. 
Olfactory stimuli i.e. presence of males or male urine exposure are capable to 
override prolonged phases of diestrus and synchronize the onset of estrus (McKinney 
1972; Barkley et al. 1981). 
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ABBREVIATIONS 
$  U.S. Dollar 
%  percent 
µg  microgram (1x10-9 kg) 
/d  per day 
µL  micro liter (1x10-9 L) 
A X B  AB6F1 mice (F1-generation; the offspring from an A/J female and a B6 male) 
AGS  adreno-genital syndrome 
ANOVA Analysis of Variance 
APACHE acute physiology and chronic health evaluation (scoring system) 
ARDS  Acute Respiratory Distress Syndrome 
B X A  B6AF1 mice (F1-generation; the offspring from a B6 female and an A/J male) 
B6  inbred mouse strain C57BL/6J 
CD-14  Cluster of Differentiation 14 
CD-4  Cluster of Differentiation 4 
CLP  cecal ligation and puncture 
CONT  control 
CX  castrated 
DHT  5α-dihydrotestosterone 
DNA  deoxyribonucleic acid 
DSMB  data and safety monitoring board 
E. coli  Escherichia coli 
EDTA  ethylene diamine tetraacetic acid 
ELISA  enzyme-linked immuno sorbant assay 
ERs  estrogen receptors 
EST  17-β-Estradiol 
F1  1st filial generation 
FSH  follicle stimulating hormone 
G  gauge, unit for outer diameter of a catheter 
g  gram (1x10-3 kg) 
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GnRH  gonadotrophine releasing hormone 
h  hours 
HLA  human leukocyte antigens 
HRT  hormone replacement therapy 
IFN-γ  interferon γ 
IL-10   interleukin 10 
IL-1ß  interleukin 1ß 
IL-2  interleukin 2 
IL-3  interleukin 3 
IL-6  interleukin 6 
kb  kilo base-pairs 
kg  kilogram 
L  liter 
LBP  LPS-binding protein 
LH  luteinizing hormone 
LPS  lipopolysaccaride 
mg  milligram (1x10-6 kg) 
MHC-I  major histocompatibility complex class 1 
MHC-II  major histocompatibility complex class 2 
ml  milliliter (1x10-6 L) 
MODS  Multiple Organ Dysfunction Syndrome 
n  number of mice in the designated experimental group 
NF-κB  nuclear factor κB 
ng  nanogram (1x10-12 kg) 
NIH  National Institutes of Health 
p  p-value, probability of a statistic occurring by chance 
PAR  pseudoautosomal region 
pg  pictogram (1x10-15 kg) 
SRY  sex-determining region Y 
TDF  testis-determinating factor 
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Th1  type 1 helper T-cell 
Th2  type 2 helper T-cell 
TLR-4  Toll-like receptor 4 
TNF-α  Tumor Necrosis Factor α 
U.S.  United States of America 
V/V  volume per volume 
VEH  vehicle, i.e. placebo-pellet without hormone 
WHI  Women’s Health Initiative 
X/X  female genotype as indicated by two x chromosomes 
X/Y  male genotype as indicated by x and y chromosome 
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